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Summary
This study is primarily a olinioal assessment of a new radioisotope 
of iodine (iodine-125) for tlie treatment of thyrotoxicosis* I was 
attracted to this project by my close association with Dr* W*E* Greig 
who pioneered this approach*
The thesis consists of three sections, A, 3 and 0. The first 
Chapter of Beotion A is concerned with the currently used treatments 
for thyrotoxicosis (Graves’ disease), special attention being given to 
iodinà-131* There is no excuse for the proportion of the Chapter 
which deals with the poor results, side effects and complications of 
the therapies, and again prominence is given to iodine-131 in particular 
the problem of post therapy hypothyroidism* Included in this Chapter 
is a personally analysed combined radio therapeutic trial using iodine- 
131 and carbimacole*
The rationale for the use of iodine-125 is detailed in Section A 
Chapter II. The rich spectrum of low energy short range electrons 
emitted from iodine-125 preferentially irradiates the hormone producing 
region a,t the apex of the follicular cells without killing the cells*
It is theoretically possible using iodine-125 to produce rapid control 
of the disease without causing post-treatment hypothyroidism. Animal 
experiments oarried out by other investigators confirming this hypothesis 
are described.
Section B consists of three Chapters wlrioh deal with the clinical 
trials of iodine-125 in patients* In Chapter I the excellent results 
of large therapy doses justified this approach and encouraged extension 
of the trials using smaller but empirical doses. The method of 
oaloula,ting the rad dose at different levels of the follicular cell is 
described^
The main clinical trial, the treatment of 265 thyrotoxic patients 
with different dose schedules of iodine-125» io detailed in Chapter II.
The outcome is related to the sex and age of the patients, the total 
dose prescribed, the thyroid sise before therapy, the dose of iodine- 
125 prescribed per gram of thyroid and the length of follow up.
Clinical trials of iodine-125 in three centres are discussed and the 
overall pattern of results integra,ted.
Complications which have arisen after iodine-125 treatment are 
included in Chapter III as are prospective investigations into 
potential hasards.
Two Chapters in Section C deal with the radiobiological differences 
in the thyrotoxic thyroid after treatment with iodine-125 compared with 
iodine-131. In the first Chapter, routine radioiodine tests, an 
Intravenous perchlorate discharge tost, radiochromatograms of serum and 
combined use of serum thyro3cine, T3 resin and T.SJI. assay are utilised.
In the second mathematical techniques are employed.
Preliminary results of certain suspects of the therapeutic use of 
lodinQ-125 have been published
Lancet (1970) 2: 840
New England Journal Medicine (l97l) 285s 1099
Further Advances in Thyroid Research (l97l)
Editors K. Fellinger and R. Hofer
Vorlag dor Wiener Mediainisohon Akadcmie P 619 
but the results in this thesis update all those in previous communications.
Reference is also made to other articles involved with (a) the 
general treatment of thyrotoxicosis, Scottish Medical Journal (1971)
16Î 519» (b) thyroid carcinoma occurring after iodine-131 treatment, 
Journal Olinioal Endocrinology (l97l) 33: 287, (0) the combined use
of carbimaîsole and iodine-131, Scottish Medical Journal (1972) 17: 57
i i
and (d) the intravenous perchlorate discharge test, Journal Olinioal.
I
Endocrinology (1972), 33s 148*
Oommunloations about the therapeutic use of iodine-125 have been 
personally presented to the following learned Societies s
Scottish Society for Experimental Medicine (Aberdeen 1970)
The Thyroid Club (London 19?l)
Tlie Fourth Meeting of the European Thyroid Association
(Dome 1971)
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ARationale for the use of Iodine-125 as an 
alternative to the currently used treatments, 
especially Iodine-131, in thyrotoxicosis.
Review of treatments of Thyrotoxicosis<
Introduotion
In this chapter the treatment of an adult patient with the 
intriguing olinioal problem of Graves* disease is considered in 
detail. Managements of hyperthyroidism due to a non endocrine 
tumour secreting T.S.H. or T.S.ÏÏ. like material (Odell et al 
1963» Odell 1968), faotitial thyrotoxicosis (Rose et al 1969), 
thyrotoxicosis due to an ovarian tumour secreting tliyroxine 
(Kempers et al 1970, Hershman and Higgins 1971) or a thyrotopin 
producing pituitary chromophobe adenoma (Hamilton et al 1970, 
Editorial 197l) are not included.
The natural course of untreated Graves* disease is described 
first to allow a comparison with the outcome following various 
methods of treatment. Radioactive iodine-131 therapy constitutes 
the major portion of the chapter and this is followed by a short 
discussion of other therapeutic approaches.
Raturai Ooime Of Untreated Thyrotoxieesle
BeoaUB© of the hi# morbidity of untreated thyrotoxicosis there 
is very little up-to-date information about the natural course of the 
disease ephrt from one report by McLarty et al ( 1971a) who followed 
the fluctuating Olinioal progress in five untreated patients with iïiild 
symptoms. Wilson (196?) deduced from survey of the literature that 
between 15 and 25 per cent of patients died as a result of their disease 
and although these percentages may not be representative for the present 
time they serve to emphasise that untreated thyrotoxicosis is dangerous* 
A larger proportion of patients remained chronically unwell and in the 
remainder spontaneous remission occurred and a proportion of these 
euthyroid patients eventually became hypothyroid (Battler 1908).
The aim of therapy is to restore the patient to normal thyroid 
function and health as rapidly as possible by the least costly method 
with the least side effects (Chapman 1971a). The logical approach 
should permanently remove the cause of the disease but despite a 
greater understending of the pathogenesis (Kriss et al 1964» Adams 1965, 
Lipman at al 1967, Hotael 1968, Ochl and Be Groot 1968, Krise 1970, 
Munro 1970, Burke 1971, Mtmro 1972) this still remains unknown and 
treatment is directed at reducing the level of circulating thyroid 
hormones to normal since the olinioal manifestations are produced by 
ohronio hyperthyroxinaemis. This can be achieved by permanent 
destruction of the thyroid by radioactive iodine or by surgery. 
Alternatively the ensymes involved in thyroid hormone synthesis can be 
inliibited by anti thyroid drugs which have the merit of doing no 
permanent damage to the gland. The treatment of thyrotoxicosis has 
been discussed in detail by many investigators (Franklin 1955, Asper 
1960, Chapman I96I, Cassidy 1962, Means et al 1963, Hershman I966,
1967» Howard 1967» Wilson 1967» Trotter 1967» Ingbar and Woebar 1968» 
MoGirr and Greig 1968, Havard 1969» Swerdloff 197G» Warner 1971* 
MoDougall and Grelg 1971 and MoGirr 1972) and in this review attention 
is foonssed on the disadvantages, side effects and oomplioationa of 
the three standard methods.
Eadioaotive Iodine Treatment ( Iodine-131)
The thyroid cells do not differentiate between radioactive and 
natural iodine and therefore a source of radiation can be localised 
within tlie colloid of the gland, and the radiations emitted destroy 
the surrounding hyperfmotioning follicular cells without causing 
irradiation damage to contiguous structures. In January 1941 the 
first thyrotoxic patient was treated with radioactive iodine (iodine 
130 half life 12.5 hours) and by the following year two groups of 
investigators reported their preliminary results with this radio­
nuclide (Herts and Roberts 1942, Hamilton and Lawrence 1942) . Until 
that time surgical thyroidectomy had been the only definitive 
treatments the operation usually being performed on inadequately 
controlled patients so it is not difficult to understand why radio­
active iodine therapy rapidly gained in favour. Tîxe radionuclide 
originally used, iodino-130, has a short half life and was superceded 
by iodine-131 (half life 8 days) which by I960 was being used to treat 
the majority of thyrotoxic patients.
Aim Of Eadioaotive Iodine-131 Theranv
Tîie aim of iodine-131 therapy is to obtain a hi# cure rate as 
quickly as possible with one therapy dose* 60 per cent of patients 
respond to the first ”drink” (59 per cent Be Gowin et al 1959, 59 
per cent Sheline and Miller 1959» 55 per cent Werner et al 1957» 59 per 
omtBlomfield et al 1959» 63 per cent Hubenfield et al 1959 and 65
per oent Cassidy and Astwood 1959) and approximately 2 out of 3 
resistant patients respond satisfaotorily to each subsequent therapy 
dose. At least 3 months are allowed to elapse between therapy drinks, 
but by delaying the prescription for as long as 6 months Chapman ( 1971a) 
has demonstrated that a further 15 per oent of patients become euthyroid 
without further radioiodine.
With conventional doses of iodine-131 about 50 per cent of patients 
remain thyrotoxic for 3 months after therapy and many of them are not 
rendered eutîiyroid for a considerable time after this. A small group 
of patients do not respond even to repeated conventional doses and may 
require several drinlcs and eventually massive amounts. Automatic 
referral for surgery should not be considered since control of the 
disease will inevitably occur with iodine-131 alone (Silver 1968).
Early Oomplioationa And Side Effects Of Iodine-131 Therapy 
1" Baaiatlon
A few days after therapy slight discomfort may occur over the 
thyroid but even mild analgesic treatment is seldom required 
(Einîîornet al 196?) * The disoorofort is occasionally referred to 
the teeth and gums (Chapman 1971a). The gland may be tender on 
palpation and localised swelling occur (Yolpe et al I960 and 1961).
A more intense reaction with severe tîiyroidal pain and fever 
occasionally follows the use of oanoer%)cldal doses of iodine-131 
(Hosohl et al 1965) and permanent hypothyroidism is the usual 
sequel of radiation thyroiditis (Schwarts 1970).
2. Exacerbation of Hyperthyroidisms Thyroid Crisis s
Exacerbation of thyrotoxioosis is not uncommon but frank 
thyroid crisis following iodine-131 has been infrequently 
documented (Rolson et al 1952, Lamberg et al 1959» Hubenfield et
al 1959» Hof al et al 1966, Viherkoski et al 1970* Shafer and Huttall 
1971* Roisen and Decker 1971) and lu some aeriee no oaaes have been 
reported (Cassidy and Aetwood 1959)- Patiente with oardiao disease 
independent of or seoondary to thyrotoxioosis are ideally treated 
wl'Mi radioactive iodine but in these Ixigh risk patients a sli#t 
worsening of the disease can precipitate a cardiovmcular death 
without thyroid crisis and they should be treated with anti thyroid 
drugs for a few weeks prior to the radioiodine.
A death occurring shortly after a therapeutic dose of ra,dioiodine 
does not necessarily mean that the radioiodine has been the cause of 
death or that it has been precipitated by thyroid crisis (Sheline and 
Miller,. 1959, Volpe et al 1961).
3- Radiation Bialitiss
Therapeutic doses of radioactive iodine espeoiaUy cancer- 
ooidal doses can cause swelling and pain in the submoxillary and 
parotid glands (Bigler and Scanlon 1955» Goolden et al 1957» 
Chapman 1971a)* The parotid is most frequently affected because 
of its hi# saliVa to serum concentration of iodine (Bustad 1972) # 
A fall in salivary amylase follows radioiodine treatment (Scîmeyer 
1953) but like the ©ialitis it is transient and subsides without 
treatment.
13%
Late Complications And Side Effects Of ' I Therapy
1. Hooplas tic Changes.
(a)
All radiation is potentially carcinogenic. Epidemiological 
surveys have shown that external radiation to the neck undoubtedly 
increases the incidence of carcinoma of the thyroid in cMldren 
(Duffy and Fitzgerald 1950» Wilson et al 1958)^ The series of
thyroid oancers in children reported hy Winship and Hosvoll (1961) 
forcibly bore out this finding* Fincue et al (196?) eetlmated that 
the incidence of thyroid nodules occurring in children who had been 
treated in infancy with % - rays for thymic enlargement was 30 per 
cent; the risk of developing a thyroid cancer was just over one 
tenth of this figure. Using data from three sources Hempelmann 
(1968) has shown that a linear relationship exists between the 
incidence of thyroid nodules and the estimated cumulative radiation 
dose to the thyroid. An association between external radiation and 
thyroid neoplasia has also been shown to exist in adults (Goolden 
1958, Willis 1959 and Wilson et al 1970).
Clinical surveillance of the atomic bomb victims of Hiroshima and 
Hagasaki (Hollingsworth et al 1963, Sooolow et al 1963) has produced 
further epidemiological evidence that radiation to the thyroid is 
associated with an increased incidence of thyroid carcinoma. A 
similar finding is reported by Conard et al (I966, 1970) in the 
Marshallese people who were accidently exposed to radioactive fallout 
on the Rongelap Islands. In the 67 islanders involved, 3 oases of 
thyroid carcinoma and 16 oases of benign thyroid nodules have become 
apparent. These people have been exposed to estimated doses of I60 
Rads from several isotopes of iodine (^^^, 132^  ^133j as
well as 175 Rad from gamma radiation. Children with small thyroid 
glands may have received up to 1,400 Rads from the radionuclides of 
iodine.
There has, however, been controversy as to whether treatment of 
hyperthyroidism with radioiodine causes a similar increase in the 
incidence of thyroid carcinoma. Experimental work in rats (Goldberg 
and Ohaikoff 1952, Donlaoh 1956) has indicated that iodine-131 will 
produce thyroid tumours in these animals especially in a hyperplastic 
gland. In humans to date there are ten documented oases of thyroid
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earcinoffla (Table Al) (Kilpatrick et al 1957, Sheline et al 1959#
Karlan et al 1964, Staffurth 1966, Biirke et al 1967, Baker 1969,
Barnard and Parsôns 1969, Staraler et al 1970, Lima et al 1970 and 
MoBongall et al 197l)# The United States environmental protection 
agency have information of 16 cases of thyroid tumours following 
iodine-131, this number includes those listed above (Tompkins 1971)* 
Many hundreds of thousands of patients have been treated with 
radioiodine most commonly iodine-131. The low incidence of thyroid 
tumours is thus very striking in view of the reported incidence of 
thyroid neoplasia in surgically treated thyrotoxic patients which 
varies from 0.15 per pent (Sokal 1954) to 2.5 per cent (Olen and 
Klinck 1966). It is possible that iodine-131 may offer partial 
protection either by inhibiting the follicular cells from becoming 
malignant (Chapman 1971b) or by destroying latent neoplasms. Althou# 
most centres in the United States treat all thyrotoxic patients aged 
20 or above witii radioiodine, in the U.K. it has remained the policy 
to restrict this fossn of therapy to patients aged 40 years Or more 
unless there are exceptional mitigating circumstances.
(b) Leulcaemia
There is evidence from several sources that radiation 
increases the incidence of leukaemia. A hi#er frequency is- 
found in the survivors of the atomic holocausts in Japan (Brill 
et al 1962) in patients with ankylosing spondylitis treated by 
X irradiation (Oouct Brom and Doll 1957) and in babies bom to 
mothers who have had diagnostic radiology during their confine­
ment (Stewart 196I). Green et al (196I) have calculated that 
1 mCi of iodine-131 subjects tlie blood and marrow to 1.7 Rada 
and thus the blood forming organs in the ’’average” thyrotoxic 
patient treated with iodine-131 receives between 10 and 20 Rads.
8
Because of the possibility that iodine-131 might be leukaemogenio 
the United States Oooperative Tlierapy Follow-up Study has carefully 
investigated this relationsMp and have recently published their 
preliminary findings (Saenger et al 1968). In this study 18*379 
patients treated with radiolodine were reviewed for 119*000 
patient year's# ■ 17 patients developed leuli:aemia. 16 in a 
surgically treated group of 10,731 patients who were reviewed for 
114,000 patient years were also found to have leulcaemia# There 
was no statistical difference betvreen the tivo groups# However, 
when corrections were made for sox and age the incidence of 
leukaemia in tliese patients irrespective of the mode of treatment 
(radioiodine or surgery) was 50 per cent greater than expected in 
the general population# Althou# tlxere has been criticism of 
their conclusions, Saengor et al (1968, I971) did not attribute 
this difference to the therapies and tlxey found no evidence to 
support the contention that iodine-131 induces leukaeraia. Their 
conclusions, tlierefore, support earlier studies (Poohin i960, 
Werner et al 1961 and McOommaCk and Sheline 1963) *
(o) Ohrcmosomal Abnormalities
Chromosomal aberrations have been demonstrated in patiente 
who have received iodine-131 (Boyd et al 1961, Cantolino et al 
1966 and Hofal and Beierwaltes I964). Many of these reports 
relate to patients who have received large doses for thyroid 
cancer and it is difficult to îoiow the relevance of the 
relatively gross abnormalities produced, since they do not appear 
to be a prodromal phase of leukaemia (Vide infra, Section B 
Chapter III), Subtle chromosomal alterations produced by small 
doses of iodine-131 may be more relevant than the devastating 
effects of large doses (Maointyre and Bobyns 1962).
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2. BxtrathvroidaX Tissue Dama^
in humans radioiodine therapy produces no detectable injury 
to the recurrent laryngeal nerves, trachea or larynx (Silver 196B) 
and tracheal compression has actually been relieved (Blomfield et 
al 1959)# Nevertheless, tracheal constriction has been found in 
the offspring of ewes fed iodine-131 î the foetal thyroids were 
probably exposed to more than 30,000 rads and the constriction 
may have been due to failure of the cartilage to develop or to 
contraction of fibrous tissue in the Irradiated gland (Bustad et 
al 1957).
Tiie maidmum range of ^  rays emitted by iodine-131 is 2000 
microns in tissues and it is unlikely that parathyroid damage 
results except when all the parathyroids are intrathyroidol- 
Ho oases of hypoparathyroidism have been noted after large doses 
of iodine-131 for thyroid carcinoma but surprisingly there are 
reports of hypoparathyroidism in thyrotoxic patients who have 
received radioiodine therapy, Table A2 (Tighe 1952, Boulet et al 
1952, Klotz et al 1953, Langerhom and Vincent 1957, Gilbert- 
Dreyfus et al 1958, Townsend I96I, Eipe et al I968 and Freeman et 
al 1969), The doses of radioiodine administered to each of these 
patients were not excessive and none was hypothyroid at the time 
they became hypooalcaemic# When stressed with E.D.T.A. (Better
et al 1969) a proportion of patients fail to maintain serum calcium 
in the normal range. Parathyroid function in iodine-125 treated 
patients is discussed below (Section B Chapter III)*
Hypooaloaemia, thyroiditis and thyroid crisis have occurred 
simultaneously in one patient (Freeman et al 1969)*
3# Fertility
Libido and fertility are decreased in active thyrotoxicosis
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and treatment of the disease in females is often followed by 
imexpeoted pregnanolea* Iodine-131 does not differ in this 
respect from surgery or antithyroid drugs (Volpe et al 196l), 
Menstrual disturhanoes have not been caused by the doses of 
radioiodine used to treat thyrotoxioosis, but very large doses 
used in the treatment of metastatic follicular carcinoma has 
produced amenorrhoea; irradiation from nei#bouring functional 
métastasés probably was the cause. 563 mOi of iodine-131 has 
produced no' testicular atrophy (Kemmer and Goodman 1969).
4* Effect on Infants Bom to Patients Treated with Iodine-131
(a) Thyroid
The foetal thyroid retains and concentrâtes iodide after the 
first trimester (Ohapmen et al 1948) and pregnancy is considered 
by all therapists to be an absolute contra-indication to radio- 
iodine therapy# Unwittingly iodine-131 has been administered to 
pregnant patients but usually no untoward effects have been found 
in the babies (Volpe et al I96I, MoGirr et al I964 and Silver 
1968) probably because the maternal thyroid by its avidity for 
iodine protects ttie infant# Foetal hypothyroidism has been found 
on six occasions, Table A3 (Russell et al 1957, Ray et al 1959,
Hamill et al 1961, Fisher et al 1963 and Ffannensteil et al 1965).
(b) Genetic
If after a’drink” no female patient becomes pregnant and no 
male patient fathers a child there will be no increase in irradiation 
Induced imitations. With the tendency to treat younger patients an 
increasing number of them do have children. To assess the genetic 
affects of irradiation the concept of the Doubling Dose is used.
The Doubling Dose is the RAD dose which eventually causes a complete 
doubling of gene mutations; it has been estimated to lie between
11
TABIE A4
Congenital Malfonaatione Following Iodine-131 
Therapy in Patiente from B.M. Chapman ( 1971a)
Normal
Congenital Heart Disease
Mongoloid (mother had mumps in 
first tremester)
Club Foot 
Deaf
Bilateral Hernia 
Mentally Retarded
XYY Karyotype 
Ureteral Strioture
Mother Given 
Iodine-131
189
2
1
1
1
1
(All in one 
family)
Father Given 
Iodino-*131
18
1
TOTAL 199 20
15 and 30 Rads (Looney 1969). This conoept is useful when 
considering populations hut does not help in advising individual 
patients. There are also difficulties in making valid oomparisons 
in the number of malformations found in children bom to parents 
not treated with radioiodine since it may be impossible to exclude 
other stimuli which could be incriminated in producing mutations. 
The congenital abnormalities in infants of one group of iodine-131 
treated patients are tabulated (Table A4)* The number or type of 
abnormality does not differ from the general population in whom 4 
to 5 per cent of all live births have congenital malformations 
(Chapman 1971&)*
5. Hypothyroidism Following Therapy 
(a) The Problem Revieited
Radioactive iodine destroys thyroid follicular cells and from 
its inception therapists expected and soon confirmed that some 
patients become hypothyroid because of excessive follicular cell 
destruction. In early reports the modal incidence of this 
iatrogenic conplioation was about 10 per cent (Soley et al 1949» 
Wayne et al 1952» Clarke and Rule 1955» Chapman and Maloof 1955* 
Beierwaltes and Johnson 1956» Werner et al 1957* Hubenfield et al 
1959 end Sheline and Miller 1959)* Some patients* having been 
unequivocally euthyroid for many years, subsequently became 
hypothyroid (Chapman and Maloof 1955)#
Deling and Einhom (196I) reported a progressive rise in the 
percentage of hypothyroid patients witl% the passage of time after 
iodine-131 therapy. Their finding was partially due to the 
methodolo^ of expressing results. If the proportion of hypo­
thyroid patients is calculated as a percentage of the total 
treatment group an artifloally low result is obtained. A greater
12
but truer result is obtained if the percentage of patients Who 
become subtbyroid are calculated year by year. There is now 
universal confirmation of the cumulative incidence of post- 
treatment îîypothyroidism (MoGirr et al 1964» Green and Vfilson 
1964» Dunn and Chapman I964» Editorial 1965» Greig et al 1966, 
Greig I966, Hof al et al 1966» Editorial 1967» Smith and Wilson 
1967b, Editorial 1968a, 1968b, Hagen 1968, Bronsky et al 1969» 
Tubiana 1971).
The main problem of hypothyroidism is diagnosis (Becker and 
Hurley 1971). Provided the patient at risk can be kept under 
medical supervision, however, the condition is seldom missed; 
reviews are best arranged with the aid of a computerised recall 
system (Philp et al 1968). Treatment with thyroxine is simple, 
cheap and efficient if regularly ingested. In many patients 
the thyroid failure is of insidious onset (Kaipainen et al 1970) 
and they are singularly complacent and uncomplaining about their 
health. One organ or system may be disproportionately involved 
by the subthyroidiam resulting in referral of the patient to a 
cardiologist, neurologist or rheumatologist (Bland and I'hymoyer 
1970) who does not suspect tlie diagnosis (Editorial 1970b, 1970c). 
A diagnostic delay is serious since severe thyroid failure can 
cause ventricular fibrillation (Maoauley and Bhepherd 19?l), 
coma (Royoe 1971) and death (Bleated and Pollock 1967a, 1967b).
A 70 per cent incidence of hypothyroidism may be encountered 
10 years after iodine-131 therapy (lofal et al 1966, Blahd and 
Hays 1972) and even then there is no evidence that the annual 
accrual rate is levelling off. There is no simple metiiod of 
predicting v/hioh patient will be affected at any specific time 
and therefore all iodine-131 treated patients must be kept under 
periodic medical review either for life or until they have been 
stabilised on thyroxine replacement therapy. Routine life-long
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pjîescriptioia of thyj?03Clno fox* all radioiodlno treated patients has 
been advocated by Selby (1965) and Bsselstyn and Orile (1971)# If 
this policy is adopted ‘^guaranteed** control with large therapy doses 
is justifiable (Hamburger and Paul 1968) thou^ certainly not ideal 
(Editorial 1968b).
W  Pause, of Hypothmoiatm
Untreated thyrotoxicosis may pass through the eutliy3:oid state 
into hypothyroidism but title does not aceoimt for the alarming 
frequency of post iodine-131 hypothyroidism. Animal experiments 
have been carried out to obtain insight about the aetiological 
factors. *Bie cell nucleus has been shown to be exquisitely radio­
sensitive and iodine-131 radiation of a thyroid follicular cell 
severe enougti to reduce hormone production inevitably interferes 
with the cell's divisional integrity (Grelg 1965, Philp I966,
Dobyns and Bidteohenfeo 1961 and bobyns et al 196?). Bie return 
of normal thyroid function following iodino-131 therapy points to 
subthyroidisffl at some time in the future since as each follicular 
cell dies I either naturally or an a result of radioiodine ttwrapy 
it fails to divide and is not replaced. *Uhie topic is discussed 
in more detail in Section A, Chapter II.
Biere are other factos^ which have been incriminated in causing 
post therapy hypothyroidism. Firstly Irradiation damage to the 
thyroid vasculature (Curran et al 1958, Btanbury and Be Groot 1964), 
but this is usually not severe enough to reduce the blood supply to 
such a degree that the colls die prematurely. Secondly irradiation 
induced autoimmune thyroiditis (Blagg I960, Einhom et al 1965,
1970) is an attractive tlieory but although there is a transient 
rise in thyroid antibodies in the serum of some patients treated 
with iodine-131, the eventual outcome cannot be closely correlated
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Dotted area - after low (50 per cent standard) doses
with the antihody titres (Burke and Silver stein 1969). It is 
now thought that this hypothesis is also incorrect.
(o) Heduotion of i^eauenov of Hypoth^oidiom
If hypothyroidism results from the irradiation damage of the 
follicular cell nuclei one obvious remedy is to administer smaller 
doses of radioiodine. l?he conventional therapy dose of iodine-131 
administered is about 160 uGi per estimated gram of thyroid and 
this subjects tlio cell nuclei to between 7,000 and 10,000 Ead.e. 
Several groups of investigators have prescribed therapy doses of 
approximately 50 per cent of this (îeaoan et al 1967, Smith and 
Wilson 1967a, 1967b, Zellman et al I960, SldLlhaan et al 1969*
Goolden and Eraser 1969 and Kaipainen et al 1970) and compared with 
"standard" therapy the hypothyroid frequency is reduced 1 year after 
therapy and even after follow up for 5 years remains lower when the 
low dose regime is used (Figure Al). There is a delay in 
symptomatic control, however, wMoh requires the proscription of 
inorganic iodine (Hagen et al 1967), thiouracils (Smith and Wilson 
1967a) or beta adrenergic blocking drugs (Hadden et al 1968, Franco 
et al 1970 and Lowe et al 1971)* Lowe ot al (1971) used a single 
dose of 2.5 mOl iodine-131 in each of their patients and even witli 
this small dose there was a very disappointing incidence of hypo­
thyroidism 2 years after therapy (19 per cent).
6. Delay in Control of Ihvrotoxioosis After Iodine-131 Therapy
40 per cent of patients require retreatment when standard doses 
of iodine-131 are prescribed* The adoption of low dose regimes to 
overcome the problem of hypothyroidism necessitates the use of anti­
thyroid drugs and often re treatment in over 60 per cent of patients. 
Tlie disadvantages and side effects of antithyroid drugs are therefore 
added to those of radioiodine therapy* Ire treatment of patients
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with anti thyroid drugs ia one method of reducing the delayed symptomatic 
control. Recently a study has been undertaken (McDougall and Greig 
1972) using standard and low doses of iodine-131 in 74 patients who 
had all been pretreated with oarbiraazole for 20 weeks. The average 
time to obtain control with oarbima&ole was 10.2 weeks despite the 
older age of the patients (38-68 years). This delay was similar to 
that experienced by Crooks and Wayne (i960). Following the course 
of carbimaaole the patients were alternatively allotted to receive 
standard or low (50 per cent of standard) doses of iodine-131. After 
the dose of radioiodine all of the patients were treated with 
oarbimaaole for a further 20 weeks. Symptomatic control was assured 
during this 10 months of anti thyroid drug therapy, thus giving the 
radioiodine therapy time to act.
Review of the patients after completion of the trial (follow up 
without antithyroid drugs 20 months) illustrated that in the standard 
dose group only 42.1 per cent remained euthyroid after 1 therapy dose. 
At that time 21.1 per cent had become hypothyroid and as many as 36.8 
per cent had relapsed. In ttie low dose group 44*4 per cent were 
euthyroid, the percentage hypothyroid was reduced to 8*4 end 47*2 per 
cent remained thyrotoxic (Table A5). The results serve to illustrate 
the poor one dose response even with standard doses of iodine-131 given 
an optimum time to act.
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Suiïimary Of Iodine-131 Therapy
The simplicity, cheapness and convenience of radioiodine therapy 
are so attractive that it is difficult to envisage any form of therapy 
superceding it until the aetiology of thyrotoxicosis is clarified.
The early side effects of therapy are rarely encountered in practice. 
Post-treatment thyroid cancer is found less commonly than it is in 
untreated thyrotoxic patients and leulcaemia although found more 
commonly after iodine-131 therapy tlian in the general population is 
no more common than in surgically treated patients. Any genetic 
risks passed on to succeeding generations are small.
Few forms of therapy are ultimately so uniformly successful since 
100 per cent of thyrotoxic patients are eventually "cured" of their 
disease though an increasingly great number perhaps all eventually 
become hypothyroid. Smaller doses used to reduce the frequency of 
hypothyroidism slow the rate of control of the disease. It is 
conceptually impossible to believe that iodine-131 could ever be 
considered the ideal radionuclide for the treatment of thyrotoxicosis 
since prompt control of the disease and reduction of post-therapy 
hypothyroidism are mutually incompatible#
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Btirgioal Treatment Of Thyrotoxioosia
Thyroideotomy was the only treatment for tliyrotoadtoosis till 
antithyroid drugs and radioiodine were Introduced in the 1940's, The 
operation was reserved for severely ill patients and the risks were 
considerable until the introduction of inorganic iodine (Plummer 1923) 
to reduce the toxicity of the patient preoperatively* With experience 
in patient selection and preparation coupled with the improvement in 
surgical technique and anaesthesia thyroidectomy is a safe elective 
procedure.
The best candidates for partial thyroidectomy are patients under 
the age of 40 Tisho fail to respond to two adequate courses of anti- 
thyroid drugs, patients with large goitres, (especially if nodular and 
causing pressure symptoms) and those witîfi single toxic adenomas (McGirr 
and Greig 1968). Patients with thyrotoxic heart disease, impalpable 
thyroid glands and severe exophthalmos are best excluded (Riddell 1965) 
and tlie risks of a second partial thyroidectomy are so great that a 
reoperation should only be considered in exceptional oiroumstances 
(Molarty et al 1969) #
It is surprising how many patients do become euthyroid after radical 
removal of an empirical volume of thyroid tissue, The results of 
operation vary considerably, this variance may partly reflect differences 
in surgical technique but usually depends on the length of follow up and 
whether surgeons or physicians review the patients* When surgeons 
report the experience the results usually show an uncomplicated cure 
rate of over 70 per cent with an overall low morbidity#
Post Operative Hypothyroidism 
Representative figures for the incidence of post-operative hypo-
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thyroidism vary from 5 per cent (Hoy et al 1967) 5,5 per oent (loleill 
and Thomson I968) 9 per cent (Painter i960) and 10 per cent (Coloook 
1962) to 25 per cent (Olsen et al 1970), 28 per cent (Hofei et al 1966) 
36 per cent (Hedley et al 1970) and 49 per cent (î-îloMe et al 1972), 
Several hut not all authors have found an Increase in the incidence of 
hypothyroidism with the passage of time, The complication is most 
likely to develop in those with circulating thyroid antibodies 
(Buchanan et al 1962, Irvine and Btewart I967) and with excessive 
lymphoid tissue in the resected thyroid (Greene 1950), The former 
group can he predicted preopemtively and should if possible be 
considered for alternative therapy unless there are pressing indications 
for operation. If operation is deemed essential, replacement therapy 
may be commenced in the early post operative period (Wilson I967). % e  
more recent reports of high and cumulative hypothyroid rates are dis­
quieting and illustrate the necessity for vigilant supervision of tlie 
surgically treated thy):otoxic patient.
Post Operative Heourrenoe Of Thvroto^oosis
%i0 recurrence rates post operatively also vary widely, from 0,6 
per cent (Painter i960) to 12,2 per cent (McHeill and Thomson I96S) 
and are usually Inversely related to the hypothyroid rate in any series. 
The results in the majority of reports are at the hi#ier end of this 
spectrum.
Other Oomulicatlons Of Thyroidectomy
Thyroidectomy necessitates a period of preoperative antithyroid 
drug therapy which may be prolonged, and a short stay in hospital 
usually between 5 and 10 days but longer if complications arise. The 
patient suffers a degree of pain. Operative mortality is extremely
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low and in several series there have been no deatlis* Wound infection, 
atelectasis, pneumonia and pulmonary embolus may arise as with any 
operative procedure (Gould et al 196g),
Post-operative thyroid crisis is extremely rare and should not■ 
occur if a careful preoperative policy is adliered to. The recurrent 
laryngeal nerve can be damaged during the operation and up to 30 per 
cent of patients notice an alteration in their voice (Painter 196o), 
Complote laryngeal nerve damage is irreversible but tlie incidence as 
judged by inspection of the vocal cords post operatively is, however, 
muoh lower, Riddell (1970) by meticulous identification of tlie 
nerves at operation followed by electrical stimulation to test each 
nerve's integrity has reduced the risk of this complication to 1,7 
per cent in a total of 1,700 operations* Bilateral recurrent 
laryngeal nerve paralysis may necessitate tracheostomy or arytenoideotomy*
A rapidly enlarging wound hamatoma may cause respiratory distress | 
in acute situations the wound has to be reopened end the blood evacuated, 
in less acutely ill patients needle aspiration of the haematoma will 
suffice.
Injury to the parathyroid glands or interference with their blood 
supply at the time of operation may lead, to acute hypocaloaemia in 2 
to 3 per cent of patients (Wade 1965), There is debate as to the 
incidenoe of ohronio hypoparathyroidism following partial thyroidectomy 
(îSdltorial I966), If 13,2).T.A, infusion is used to artifioally produce 
hypocalcaemia and test parathyroid reserve up to 25 per cent of patients 
may bo deficient (Jones and Pourraan 1963), The importance of this 
biochemical defect is uncertain since the patients are asymptomatic. 
Overall about 4 per cent of patients require prolonged replacement 
therapy witïi calcium and vitamin 3) (Wade 1965), An alternative cause 
of hypocalcaemia in post operative patients, who are in negative calcium
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balance with calcium deficient bones (Miohie et al 1971) is reversal 
of #ie deficit allowing the rapid transfer of calcium Into the skeleton 
with the inevitable onset of hypooaloaemia.
An important post operative complication espeoially in the young 
female is an ugly keloid.
Surgery for thyrotoxicosis la not to be li^^tly embarked upon. 
Careful scrutiny of the results shows a not inconsiderable number of 
patients with ohronio morbidity directly related to the procedure 
(Editorial 1970a) » In a recent study (Hedley et al 1970) only 55 per
cent of patients were unequivocally euthyroid.
Drug Therapy For Thyrotoxicosis
One important advantage of anti thyroid drugs is that no permanent 
damage is done to the thyroid. The most satisfactory and best under­
stood of the drugs used arc the imidazoles and thlouraoils. These 
drugs are equally effective when used in comparable doses (Wayne i960) 
but even under optimum conditions there may be a mean delay of 9 weeks 
(Crooks and Wayne 196O) to 10 weeks (McDougall and Greig 1972) until 
the patient is euthyroid. After a full therapeutic course (l8 months) 
on average about 50 per cent of the ps,tients will suffer a relapse and 
those who remit would probably have done so spontaneously (Wilson 1967), 
There is no good way of predicting the outcome in a particular patient, 
although two clinical features, a short history of thyrotoxicosis prior 
to commencing therapy and shrinkage in the size of goitre during 
treatment are favourable they do not inevitably point to a successful 
outcome following drug therapy (Hershman 1967).
Tiae triiodothyronine suppression test has been tried as an index 
of predictability, return of supprescibility during the course of 
anti thyroid drugs has been accepted by some workers (Alexander et al 
1966, 1967, 1970) to indicate that remission will occur on stopping
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the dmgs and likewise failure of euppreesion has been taicen to indicate 
continuing disease and likely relapse. Recent studies have shown tliat 
individual oases do recur after suppression has returned to noasnal 
(Wils and Kloppenbog 1970a, 1970b) and tlie test has little value in 
practice (Lowry et al 1971)• Using a variety of indices before and 
during therapy with the aid of computerised multidimensional analysis 
it may be possible to separate those who will remit from those who will 
not (McLarty et al 1971b) but this technique is at present only available 
for research purposes.
Because of the poor response following a standard course of drugs 
some investigators in the U.S.A. have prescribed antitliyrold drugs over 
an indefinite period to control thyrotoxicosis (Hershman et al 1966). 
Conventional anti thyroid drugs have an unfortunate habit of causing 
reactions and although these usually occur within a few weeks of 
commencing therapy (Howard I967) they may occur once maintencnoe therapy 
has been established. The overall incidence of side effects is about 
5 per cent (Greene and Morgan 1956) the most common being a maoulopapular 
rash. Other side effects include fever, alopecia, lymph node enlargement, 
gastric upset and conjunctivitis. Agranuloytoeis occurs in about 0.5 
per cent of patients? aplastic anaemia (Burrell 1956) is exceptionally 
rare.
Inorganic iodine (Plummer 1923) is not routinely used because of its 
transient symptomatic control. Iodine may have a detrimental effect on 
patients with an organic binding defect (Braverman et al 1969, 1971) and 
it may precipitate thyrotoxicosis, Jt can cause an aonefom skin rash 
and sialadenitis. Potassium perchlorate although tents/bively claimed 
to be the antithyroid drug of choice just over a decade ago (Crooks 
and Wayne i960) is now seldom used because several cases of fa.tal 
aplastic anaemia have been attributed to it (Editorial 1961, Hobson
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1961, Joîmson and Moore 1961, Krevane et al 1962.)
Melioration of thyrotoxiOoBis may be produoecL by druge which 
eelectively interfere with the production or action of oateoholaminea. 
lleeerpine (Canary et ai 1957) le useful in thyroid crisis (Dillon et al
1970); guanethidine is as effective but is slow to act (Riddle and 
Sohwartz 1970). The side effects of these drugs are, however, not 
tolerated with equanimity by most thyrotoxic patients. Propranolol 
attenuates the positive inatropio and chronotropic effect in the thyro­
toxic patient (Wiener et al 1969, Levey 1971) end has been used in 
thyroid storm (Das and Kreiger 1969), in the preparation of patients 
for thyroid surgery (Vinik et al 1968) and in conjunction with radio- 
iodine therapy (Franco et al 1970, Hadden et al 1968). These drugs do 
not influence the underlying disease process and their use alone often 
leaves the patient unwell.
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Sumyiamr
Althou#! each of the three currently used metJiode of treating 
thyrotoxicosis has its enthusiastic proponents none is ideal. The 
disadvantages of surgery include preoperative preparation, surgical 
morbidity and a very hi^ incidence of postoperative hypothyroidism. 
Drag therapy even if protracted for up to two years has the 
disadvantage that less than 50 per cent of patients have a lasting 
remission. The rising incidence of hypothyroidism following iodine- 
131 therapy should not cause a resurgence of these approaches.
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Section _ A
Chanter II
Choice of Iodine-125 as an Alternative to 
Iodine-131 in the Treatment of ThyrotoxLcoeie
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Section A 
Chapter XI
liitrcduotlon
Despite the slow rate of control and the cimnlative incidence of 
hypothyroidism after radioiodine-131, the simplicity, inexpensiveness 
and eventual effectiveness are so advantageous that the concept of 
radioiodine therapy should he retained at least until the cause of 
Graves* disease is elucidated. In the previous chapter the likely 
cause of hypothyroidism, intense nuclear irradiation, was introduced 
and the ideal radionuclide should therefore not subject this part of 
the cell to hi^ doses of radiation. After careful analysis of the 
pathologioal anatomy and pathophysiology of Graves* disease, Grelg 
(1968) suggested that iodine-125 because of its unique spectrum of low 
energy electronic emissions might be of value in rapid and permanent 
control of this condition without causing thyroid failure. To Illustrate 
the rationale of this hypothesis relevant details of the mioroanatomy 
and physiology of the thyroid are described and the pathogenesis of 
Iodine-131 induced hypothyroidism reviewed in more detail. The decay 
of iodine-125 and its emissions are discussed and finally important 
radiobiological differences between iodine-125 and iodine-131 in the 
experimental animal are summarised.
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Ma^aromatlo :e©presentation of a thyxotoxio follicular 
cell. 5?he eteps in syntheois and probable Bite of 
thyroid hormone production are ehom numerically.
(1) Trapping of inorganic iodide
(2) Oxidation of iodide to iodine
(3) lodination of tyroeine at cell apex 
Coupling of monoiodotyrosine (MT) and diiodo- 
tyroaine to form triiodothyronine (T3) and 
thyroxine (T4)
(4) Pinooytosis of thya?oglobulin
(5) Proteolysis with release of T3 and T4
MloroBoopio Anatomy of Thyroid Polliole an,d Follicular Cell
Tiie follicle is t!ie baaic unit of the thyroid and the same general 
structure appertains to normal and thyrotoxic follicles (Heimann 1966)* 
It is a rounded structure with a mean diameter of 300 microns (Hawson 
et al 1964) composed of a rim of follicular epithelium one cell in 
thickness surrounding a central core of colloid (Klinck 1964). Between 
twenty and forty follicles are closely grouped together to form lobules 
which are subunits of the thyroid lobes. Tlie normal follicular cell 
is ouboidal in shape (Wissig I96O, 1964) its apex abuts on the colloid; 
the centrally placed nucleus lies about 2 to 3 microns from this 
junction (lupulesou and Petrovici 1968) •
In thyrotoxicosis the appearance of the follicular cells are 
altered (Boniach 1967, Heimann 196?) • They become hypertrophied and
are columnar in shape and undergo hyperplastic changes. The nucleus 
lies towards the base and the distance from the nucleus to the apical 
margin is increased to between 10 and 19 microns. The apical margin 
develops prominent microvilli. The colloid volume diminishes and 
increased follicular cell sise coupled with cell rmiltiplioation 
produces infolding and projection of papillae into the colloid 
(Sommers 1968). The significance of these histologioal alterations 
will be discussed below in relation to the microdosimetry of iodine*
125.
Phvslolofsv: Formation and Secretion of Thyroid Hormones 
Synthesis and secretion of thyroid hormones (triiodothyronine and 
thyroxine) are the main functions of the colliole cell# The synthetic 
pathway (Figure A2) commences with trapping of circulating inorganic 
iodide* Tiae trapping mechanism is probably a function of the base of 
the cell (Be Groot 1969)* Iodide is then oxidised to iodine and
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attached to tyrosine, one of the constituent amino acids Of colloidal
thyroglobulln# Monoiodotyroaine (MIT) is formed when one atom of
iodine is incorporated, and diiodotyroaine (BIT) if another iodine sub­
unit is added. This very importmit step of lodination takes place at 
the apical surface of the follicle cell (stein and Gross I964, Hadler 
1969a, 1969b, Sommers 1968) in close proximity to the microvilli which 
project into the colloid.
The iodotyrosines then couple to form the complete functional 
thyroid homones, triiodothyronine (î£ET plus DIT) and thyroxine (BIT 
plus BIT). This reaction probably takes place in the colloid and may 
be related to the steric structure of thyroglobulin allov/ing tJio 
constituent molecules to lie in close proximity with one another# 
Preformed hormones remain stored within the colloid and their release, 
which is accelerated in thyrotoxicosis, is brought about by intra­
cellular ensymatic degradation of thyroglobulin. The sequence of 
events is that the cell is stimulated by long acting thyroid stimulator 
(T.S.H. in physiological oircumstances) an activator of adenyl cyclase 
the enzyme responsible for the formation of cyclic A.M.P. (Deles and 
Peake 1968)$ Cyclic A.M.P. may then stimulate pinooytosis of droplets 
of colloid. Intracellular lysosomes coalesce with the absorption 
droplet and cause protootytio degradation of the thyroglobulin moleoule 
releasing the active hormones (Fawcett et al 1969, Oatt 3.970).
Two of the most important steps in hormone synthesis end release 
lodination of tyrosine and pinooytosis of the colloid are functions of 
the apical cell margin.
Hypothvroidiam After Iodine-131 'Therau.v for Thyrotoxicosis
Gmrrently there is very substantial evidence that nuclear radiation 
damage is the cause of the progressive rise in hypothyroidism noted after 
iodine-131 therapy (Greig 1969)* Iodine-131 (half life 8 days) emits 
JB and / rays. The average energy of tl%e p rays is I87 K©v and these
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emissions are absorbed over a path of 4OG to 2000 microns* The rays 
have little therapeutic benefit since they aa:e mostly unabsorbed by the 
thyroid (Bonlaoh 1972)* Tlie radiation field of iodine-131 when stored 
in the colloid ia relative3.y great in terms of follicle cell height 
(15 microns) or even follicle diameter (300 microns)* Sven allowing 
for diffe:rences in iodine uptake and turnover in individual follicles 
the maj03?ity of these units in diffusely enlarged thyrotoxic glands are 
subjected to uniform irradiation because of crossfire between adjacent 
follicles. The only exception to this is a narrow rim of peripheral 
follicles (Anspaugh 1965)* Analogous to this is ihe fact that each 
part of the follicular cell, nucleus included, lies in this uniformly 
irradiated field*
Cell viability and ability to reproduce depend on the integrity o f 
the nucleus* The metabolic functions of the tliyroid cell have been 
shovm to be considerably more resistant to radiation than the cell's 
reproductive capacity (Glucksmann 1934) even in thyrotoxicosis \ihen 
hormone synthesis is less radioresistant* Hormal secretory capacity 
may be possible in a cell which at the end of its normal life span will 
not reproduce itself (Skanso 1948, Maloof et al 1952, Dobyns et al 1953, 
Doniaoh 1958, Bobyns and Bidtsohenko 196I, Bobyns et al 1967, Boniaoh 
1972)* Progressively larger doses of radiation not only slow or halt 
cellular mitosis but may s?norten the cells life span (Al Hindawi and 
Wilson 1965) or cause immediate cell death* "The comparative radio­
sensitivity of the nucleus is due to its content of unique maoromole- 
cules" (honiaoh 1972)* Lethal damage is followed by shrinkage of 
the thyroid and total replacement with fibrous tissue and hyaline 
material (Williams and Vickery 1965)*
The aim of iodine-131 therapy is to cause a reduction in -thyroid 
function* It is inconceivable that iodine-131 because of its lengthy 
irradia/fclon path vfill ever preferentially diminish hormone synthetic
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Table A 6
Haâioigotopes Of Iodine 
(After Myere 1966)
Mae 8 Eumber Mode of Beoay (MoV) Half Life
117 Electron capture, 6.5 minutes
118 4 ^  Electron capture 54^ B"* 13*9 minutes
119 49^ Electron capture 519^ 19*5 minutes
120 4.0 1.3 hours
121 Electron capture, 1.1 B*^ 2.1 hours
121 m Isometric transition 80 microseconds
122 Electron capture, 3.1 B**' 3.5 minutes
123 IQQP/o Electron capture 13.3 hours
124 Electron capture, 2.2 B"^ 4.2 days
125 100/y Electron capture 60.0 days
126 Electron capture, 0.57 B 13.3 days
126 m 2.6 hours
127 Bon Radioactive
128 2.12 B" 25*0 minutes
129 0.15 B"" 16 X 10^ years
130 1.02 B" 12*5 hours
131 o|6l B" 8.0 days
132 2.12 B“ 2*3 hours
133 1.30 B" 21 hours
134 2.5 B" 53 minutes
135 1.4 B~ 6*7 hours
136 5.6 B~ 83 seconds
137 B“ (n) 22 seconds
138 B” (n) 5.9 seconds
139 (n) 2*J seconds
fimotion. Any lessening in liyperseorotion idiioh results in the recovei^ 
of the patient inevitahly indicates that the radiosensitive nuclei have 
been damaged| tîiyroid failure is predictable at some time in the future, 
the speed of onset of liypothyroidism being dictated by #%e amount of 
nuclear damage. Uniform cell death after very large therapy doses will 
cause early onset hypothyroidism whereas unl.fom cellular sterilisation 
without cell loss will cause late onset hypotliyroidism. #ie rate of 
turnover of follicular cells althou^i not known is minimal, most of the 
cells may not be replaced in a normal individual's life (Doniach 1971)« 
Sheline (1969) found that less than 1 in 250 cells labelled witl% 
tritiated thymidine, suggesting that the remainder are in a resting 
phase and the delay in appearance of hypothyroidism in those patients 
with thyroid cell sterilisation is therefore related to ttxe low rate of 
cell renewal. In the majority of iodine-131 treated patients a spectrum 
of cell death and cell sterilisation exists hence the variations in time 
of appearance of thyroid failure.
Theoretically, therefore, the aim of radioiodine therapy should not 
be uniform irradiation of the whole thyroid but selective damage of the 
hormone synthetic function. This is not possible with iodine-131 
irrespective of dose manipulations* Iodine*125 has physical properties 
described in detail below which are almost ideal in preferentially 
irradiating the apex of the cell (the radioresistant functional part) 
and protecting tlie mclous (the radiosensitive divisional region).
Discovery of Iodine#125
Iodine-125 discovered in 1946 by Reid and Keston is one of the 24 
radionuclides of iodine (Table A6). A sample of tellurium had been 
bombarded with deuterons at tîxe Massachusetts Institute of Technology 
and allowed to deoay for six months.. Originally it was thou^t #xat 
the long life radionuclide iodine-129 had been isolated but subsequent
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m a m m  a 3
Mode of Decay Energy Half Life
150 Kev 60 i 0.5 days
53
100 per cent electron capture
35 Kev 1.6 x lO'^aeos
52
93 per cent internal 
conversion 
7 per cent démission
V
0 Kev 0
52
osqjeriments proved that the radioîïuollde was iodine**123 (half life 
60 2 0*5 days).
phy^ loal..,Bepiay..^^^ .^.......................(F im re  J ^ )
The complex decay scheme of lodlne-125 has been studied by several 
groups of investigators (Bergstrom 1951, Friodlander and Orr 1951# Bow 
and Axel 195&, Myers and Vanderleeden I960, Freige et al 1968, Brtl and 
Felnendegan 1969, Brtl et al 1970, Gillespie et al 1970 and Feige et al
1971)# Tho data of Gillespie et al (1970) has been used in this thesis 
for the disoussion below and for calculations of microdosimetry (Section 
B, Chapter I). Their results are in close agreement with those of 
other investigators*
Tlxo decay of iodine-125 occurs in two steps (l) transmutation to 
the metastable state of tellurium-125 by electron capture (half life 
60 i 0*5 days)* (2) Tellurium %25 decays to tellurium in the ground 
state either by the emission of X radiation or by internal conversion 
(half life 1*6 X 10**^  secs).
(1) l^lecia^n Oarture occurs predominantly from the K shell (82*2 per 
cent) the remaining transitions oooxu? from the (14*4 per cent), 3^^ 
(0.4 per cent) and 1 shells (3*0 per cent) (Wapstra et al 1959)* This 
process utilised 115 Kev of the total 150 Kev of iodine-125* Every 
captured electron converts a nuclear proton into a neutron and a 
neutrino; the emission of the neutrino imparts a nuclear recoil of 
0.1 Kev,
(2a) y Radiation: 7 per cent of the transition of metastable tellurium 
to the ground state occurs by the emission of Eradiation and by 
theoretical conversion coefficients oalcu3,ated by Sliv and Bland (1961) 
and tabulated by Lederor et o3. (1967), Gillespie et ol (1970) have 
shown that the radiation is hi#3y converted, 78 per cent, 11 per cent,
1 per cent and 3 per cent in the K, and M shells respectively.
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(âto) Internal Convegslons Energy luaparted on the excited miclem i« 
transferred to the atomic shells causing the eaqmlsion of electrons 
from their orbits# Each emitted electron has m  energy equal to its 
original excitation energy minus the binding energy. Electrons may 
be emitted from K, H shells# 78 per cent of all electron
emissions are f^m the inner shell and #iey have #ie greatest binding 
energies. (The energy of these emitted electrons is only 3.7 Kev 
(35# 5 31 «8 Kev). 10 per cent are transitions tdlth an energy of
30.5 Key (35*5 - 5*0 Kev), 1 per cent are conversion electrons 
with an energy of 30.^ Kev (35*5 4.6 Key) and 4 per cent are M Shell
emissions of 34*5 Key energy (35*5 * 1*0 Key).
Biese processes create 153 electron holes# 100 from the original 
step of electron capture and 93 from the internal conversions. Outer 
shell electrons replace the gaps in the inner shells and because of 
the difference in binding energies an excess is created iMch is 
dissipated as soft x^rays. The transfer of energy to less tl#itly 
bound electrons in the outer orbits may also cause these electrons to 
be ejected as low energy Auger or Coster Kronig electrons# The photon 
emissions with their respective energies (e ) » abundance (a) and Key are 
listed in Table A7* Table a8 gives tlie same information about the 
electronic emissions# #loh are mostly of very low energy# Ko P 
particles give rise to useless radiation and 95 per cent of them travel 
less than one micron#
Micrcsconio Inhomoaeneitv Of Radiations Prom Iodine~125
Althou# almost 70 per cent of the energy of iodine*125 is accounted 
for by the low energy X and 2^ rays only a small amount of this is absorbed 
within the thyroid. The reason for this is that the half-value thick­
ness of the majority of the photons especially those in the range 24*5 
Key to 35*5 Kev Is considerable and they pass throng the thyroid without 
depositing energy (Table A9 from Oreig 1970)* The low energy Te t
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KeV/pm
100
1-125 ELECTRONS -  ENERGY LOSS WITH 
DISTANCE
34 5 
KeVI
10 15 20
Distance from origin (pm)
Eange in tissues of the electronic emissions of different 
energies from a point source of lodine^l25#
1-125 ELECTRONS-DOSE DISTRIBUTIONS (Planes)
^  5 IxlO^
Semi-infinite plane source 
8 p Thick source 
4p Thick source 
2 p Thick source 
Thick source
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
Distance front surface (pm )
Decrease in the dose rates with distance from plane 
sources of iodine-125 of different thicknesses (l, 
2, 4 and 8 microns and a seml**lnfinite source).
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1-125 ELECTRONS-DOSE DISTRIBUTIONS 
(Spheres)
Infinite plane source 
70 p Sphere 
35 p Sphere
-16 -12 -8  -4  0 4 8 12 16 20
Distance from surface (pm)
Hapid fall-off in dose rate across the honndary of a 
sphere #ien all the iodine-125 is within the 
oironmferenoe of tlie sphere^
IlGtfBii! A 7
1-125 ELECTRONS & X-RAYS-DOSE 
DISTRIBUTION. (Follicle)
(Ok.
% %
a
S'
350
3004
250
2001
150
1001
50
(D
A B
A=all 1-125 in colloid 
B = 90% "
C " mean total gland dose
5 10 15 20 25 30 35 40 45 50 55 60 65
Distance from centre of follicle (pm)
 COLLOID-------- 1—  CELL--- 1
Rapid fall In radiation dose from the oolloid across the
apex of the follicular cell towards the hase of the cell
A. When 100 per cent of iodine-125 is in the colloid 
B* Wlien 90 per cent of iodine-125 Is in the oolloid and 
10 per cent in the cell 
C, Mean total gland dose
gable A 9
Approximate Range of Bmiosions of Iodine-125 in giosues
(From Groig 1970)
lumber per 100 Diointegratione Approximates Range (Microns)
Photons
23 100
112 30 % 10^
2# 50 % 10^
7.3 70 % lO^
Slectrons
376 0.02
78 0.#
156 0.40
15.4 12,00
8.8 15,00
12.0 22.00
3,7 26.00
X raye (3.7 Kev) are aiiaOBt ail abeorbed in the thyroid but In the rat 
these emissions and the ^ rays are responsible for only about 15 per 
cent of the absorbed dose in the gland; in the larger human thyroid 
this may be increased to 20 or 25 per cent.
The majority of the energy deposited in the thyroid is therefore 
due to the low energy electronic emissions. Gillespie et al (1970) 
and Oreig (1970) have calculated that from a point source of iodine- 
125 few electrons travel more than 15 microns and the maximum range 
is 26 microns (Figure A4). Table A9 lists the quantity and range of 
the emitted electrons in tissues. A similar pattern is true for 
iodine-125 radiations from plane sources of varying thicknesses; a 
rapid fall off in dose rate occurs in the first few microns from the 
source and this is most apparent idien the source is only 1 micron 
thick (Figure A5).
From a spherioal source of iodine-125 there is a dramatic fall 
off in dose rate across the sphere boundary (Figure A6), and alteration 
of the sise of the sphere from 35 microns to JO microns (chosen for 
similarity to proportions of colloid in rat follicles) does not 
greatly alter this. Factors which do affect the absorbed dose rate 
(rads per mOi per day) are differences in the sisse of the gland and 
changes in the relative proportions of the radionuclide within the 
colloid or the follicular cell (Figure A7). Iodine-125 has to cross 
the cell to be Incorporated in the thyroglobulin and it re-enters the 
cell when resorption and proteolysis of oolloid containing iodine-125 
occurs. Even considering these factors the intracellular content of 
iodine-125 Is not greater than 10 per cent and may be closer to zero 
(Radier et al 1962, Wetzel et al 1965) # thus 90 per cent or more of 
the radionuclide is in the colloid.
The total radiation dose from iodine-125 (electronic and photon) 
compared with Iodine-131 on the thyroid is Illustrated diagramraatioally
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Dlagramatio comparison of iodine-131 and iodine-125 
radiation effects across a thyrotoxic follicular 
cell, showing dramatic drop in radiation dose across 
the cell from iodine-125 and uniform dose rate from 
iodine-131^
in Figure A8. 'The iraportaîice of thie rapid fall off in radioactivity 
is disouesed below in relation to the radiobiologioal effects in the 
03îperlïïiental animal* Oaloulations of follioular cell rad doses in 
thyrotoxic patients treated with iodine-125 are based on the principles 
outlined above (Section B, Chapter l).
Production Of Iodine-125
Inhere are several methods of producing iodlne-125 (Myers and
Vanderleeden 1%0, Harper et al 1563)* %he method described below is
used by the Hadioohemioal Centre (Mersham) who supply the therapy doses.
Enriched Xenons 124 is irradiated for one month at a flux between
1 to 2 X neutrons per cm per om^ . She material obtained contains
equal amounts of iodine-125 and iodine-126 and it is left to decay for
several months to allow iodine-126 with a short half life (12*8 days) to
disappear. The eventual combination contains less than 1 per cent
iodine-126 and this can be further reduced using a loop process
circulating throu^ charcoal*
Cost Of Iodine-125
At the present time the cost of iodine-125» &2.00 per mOi, is
greater than had been envisaged (Myers 1965)* %ere is, however, a
greatly expanding market for iodine-125 for in vivo and in vitro
diagnostic applications* If the therapeutic possibilities discussed
below are substantiated this market will be considerably expanded.
Iodine-131 costs 00.20 per nfJi but its sales have reached a plateau.
Continued expansion of sales of iodine-125 at the present rate will
bring the relative costs of these radionuclides to 01.00 and 00*20
per mCi in 5 yoars time and 00*50 and 00*30 per mCi in a decade.
Hon IJheraneutio Hsea of Iodine-125 Based 
On Physical Properties Of The Radionuclide
Myers (1965) reviewed over 90 published reports of the uses of
iodine-125 which had been developed in the 4 years following its
34
•’médical renalscenoe”. •She half-life of 60 days provided a conveniently
long shelf life to allow preparation and transport of doses anywhere in 
the world with no material loss of radioactivity* The emissions have 
an enormous potential for both in vivo and in vitro medical and bio­
logical investigations* Because of the low intensity of the photons, 
thinner crystals and less shielding are necessaary and counting apparatus 
can be easily handled and inexpensive*
Thyroid scanning may very satisfactorily be done using the 27*2 Kev 
to 35*5 Kev photon emissions (Charkes I964) and iodine-125 has been used 
for routine thyroid function tests (Ben Porath et al 1966) corrections, 
however, must be made for the size of the thyroid (Hollo 1971)* The 
high Y to p ratio reduces the total body radiation dose which is 
important if this radionuclide is used for in vivo diagnosis in children 
(Hiooabona, 1965)* Measurements of bone density are possible using 
iodine-125 as a source of soft x rays (Cameron I964)* The low energy 
conversion and Auger electronic emissions are ideal for hi^i resolution 
autoradiographs (Andros and Wollman 1964, Hoyan et al 1963, Stein and 
Gross 1964).
Summary of Emissions of Iodine-125: Halation to
Theoretical ÏÏse in Treatment of Thyrotoxicosis
The abundance of low energy electrons from iodine-125 in theory 
suggest that if this radionuclide is used therapeutically, the 
functional segment of the follicular cell, the apex, should be subjected 
to a much higher dose rate than the nucleus* The dose rate across the 
cell does not fall to zero, however, because of the photon emissions, 
but the rad dose at the oolloid cell interface is 3 or 4 times that at 
the nuclear level, 10 microns from the oolloid (Gillespie et al 1970,
Wemer et al 1970)* However, by incorporating a quality factor to convert 
the dose rates from rads to rams the membrane dose is increased to about 
6 times the dose at the nucleus (Lewitus et al 1971)* The reason for
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this is that the quality factor is greater than one for the low energy 
electrons which travel 0*05 to 0*5 microns and hence preferentially 
irradiate the apical segment. Since these electrons do not travel as 
far as the nucleus the quality factor at that level reniains one mid the 
dose is the same in rads or rems.
To examine whether iodine-125 preferentially does reduce hormone 
synthetic function several groups of investigators, not all interested 
in its therapeutic application, have compared the effects of tMs radio­
nuclide with iodine-131 in experimental animals^
Ba^ioMologlqal. Mteots. of Iodine-125 in
Experimental Animait Gomparison With Iodine-131 
A useful technique for assessing the degree of thyroid radiation 
damage is to measure the growth response of the gland to a goitrogenic 
stimulus (Boniach and logothetopoulos 1955)* Gross et al (1968) have 
compared the respective radiation effects of iodine-125 and iodine-131 
utilising this technique. Iodine-131 in increasing doses progressively 
diminished the expected goitrogenic response probably because of intense 
nuclear irradiation. Iodine-125 in equivalent doses did not interfere 
with this response and indeed the total thyroid D.H.A. content was 
increased in animals treated with this radionuclide. Nevertheless 
rats treated with iodine-125 grew less well than those treated with 
iodine-131. This apparent paradox was attributed to an exagerrated 
destruction of thyroid hormone, especially iodothyronine, biosynthesis 
in the former animals. The pituitary glands from iodine-125 treated 
rats were significantly heavier than those of controls or of animals 
treated with iodine-131 suggesting that there was an increased secretion 
of pituitary thyrotropin in response to the reduced thyroxine pro- 
dunotion. The normal goitrogenic response illustrated that the 
follioular cells were still capable of responding to T.S.H. by 
producing D.N.A. and becoming hypertrophic. In a separate investigation 
Gross et al (1968) found two thyroid tumours in rats treated with
36
lodjlîie-125*
Iodino-125, therefore, causes a relatively greater reduction in 
thyroxine synthesis than does iodine-131; thyroxine production is 
partly a function of the follicular cell apex. Iodine-131 on the 
other hand predominantly affects the response to thyrotropin and D.N.A. 
production both of which are regulated in the basal segment of the cell.
Greig et al (l9?0) have investigated the survival of rat thyroid 
cells after irradiation by iodine-131, iodine-125 and X rays respective­
ly. Because of the extremely low rate of follioular cell proliferation 
in euthyroid ra,ts an artificially increased rate was induced by methyl- 
thiouraoil to facilitate the measurement of any differences. The Do 
values for x rays, iodine-131 and iodine-125 were 450 rads, 5,500 rads 
and 9,400 rads. The explanation for the difference in Do values for 
the two radionuclides was the inhomogeneous absorption of radiation 
across the follicular cells in the iodine-125 treated rate which 
significantly reduced the nuclear doee rate. The intense apical 
cytoplasmio dose did not, therefore, appear to be important in the 
maintenance of cell viability or reproduction. IHiis thesis has been 
confirmed by the investigation of Munro (l970) who found no reduction 
in viability of Chinese hamster fibroblasts after intense ^  irradiation 
of the cytoplasmjUnclear radiation rapidly induced death of the cells. 
Bed blood corpuscles are not killed unless subjected to very large 
doses of radiation (Schiffer et al 1966) probably because they are non 
nucleated.
An elegant series of experiments to compare the radiobiological 
effects of iodine-125 and iodine-131 in rats have been conducted by 
Vickery and Williams (1971) and they confirm that iodine-131 in 
increasing doses produces a progressive diminution of the expected 
response to a goitrogen. Tiie effect of iodine-131 was increased if 
before the radionuclide was given the rats were fed an iodine deficient
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diet to increase the thy^ zoidal uptalce of ra,dloiodlne-131. Iodine-125 
did not diminish the goitrogenic response or produce the same degree of 
thyroid destruction in rats fed a normal diet and despite the increased 
radionuclide uptake after a period of reduced iodine intalce there 
surprisingly even less inhibition of goitrogonesis or cell destruction.
Iodine deficiency produces histological alterations in the 
follioular cell similar to those encountered in thyrotoxicosis. llie 
nucleus lies basally in the follicle cell which becomes columnar in shapes 
It is, therefore, at a greater distance from the colloid and lience the 
iodine-125 irradiation source. The Influence of this gap, probably 
about 10 microns, on the radiobiological effects of iodine-125 was 
dramatic. In the rats fed on a normal diet the ratio of destructive 
effectiveness of iodine-131 to iodine-125 was 18 to 1 (Vickery and 
Williams 1971)# Calculations from iodine deficient animals gave a 
ratio of 60 to 1, iodine-125 produced even less cell destruction than 
it did in normal glands.
In animals treated with small doses of the radionuclides, nuclear 
aberrations typical of irradiation (Maloof et al 1952, Vickery 1964) 
were more common in the iodine-131 treated animals. Large doses of 
iodine-131 (300 uOi) cause severe and widespread damage and resulted 
in total fibrous replacement of the gland yet the same large doses of 
iodine-125 resulted were associated with "excellent preservation of 
structure"•
Jongejan and Van Dutton (1972) have designed a trial of experiments 
to compare the radiation effects of different doses of iodine-131 and 
iodine-125 on functions located at the level of the apex, at the nucleus 
and at the base of rat and mice follioular cells. They selected (a) 
production of thyroid homones (b) the maintenance of cellular 
structure and (c) the integrity of the iodide concentrating mechanism 
as representative functions of these respective levels. The degree of
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iîîllibition of each of these processes has been measured in experimental 
animals treated with these radionuclides.
Iodine-131 was twenty times as effective as iodine-125 in reducing 
the level of circulating thyroxine, sixteen times as potent in producing 
nuclear damage and twenty times as effective in suppressing the iodide 
trapping mechanism. It is relevant that the relative cellular 
destructive effects of the radionuclides in the experiments of Jongejan 
and Van Putten were almost identical to the results obtained by Vickery 
and Williams (1971). The former authors believed because they were 
unable to demonstrate any gross variation in the radiation effects of 
iodine-125 across the length of the cell that iodine-125 has no 
extranuclear effect and they cited as additional evidence the work of 
Schiffer et al (I966) who have shown that radiation of the red blood 
corpuscle does not affect its function. Their conclusions are, however, 
open to discussion. Primarily there is no experimental evidence ttiat 
the apical functional m?ea of the follioular cell responds to radiation 
in the same way as the red blood corpuscle. Clinical evidence will be 
presented below to suggest that there is a difference in effect of 
iodine-125 and iodine-131 and that the action of iodine-125 is not 
solely a nuclear effect.
Lewitus and Shaham (l97l) studied various parameters of thyroid 
function in rats treated with iodine-125* Even without the 
administration of a goitrogen the mass of the thyroid was found to 
Increase from one week after administration of iodine-125 and this 
persisted for 3 months. These animals nevertheless had deficient 
hormone synthesis and pituitary T.B.H. was probably the stimulus for 
thyroid enlargement. Similar findings were described by Konecny 
(1969) who also confirmed that radiation changes in the thyroid were 
of much less degree in iodine-125 treated animals compared with iodine- 
131.
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Bia^aïûatio comparison of the raxtiation effects of 
ioaine-^ 131 mid iodine«ia5 in thyrotoxic follicular 
cells.
®ie uniformity of the results in these experiments oonfirm that 
in the thyroid of experimental animals the effects of iodine-125 are 
different from iodine-131* The former radionuclide caused marked 
reduction in hormone synthesis which was easily explained hy the 
intense irradiation of the cell apex by low energy electrons (3,7 Kev 
and loss). Althou^i about 4 cent of the electrons travel as far 
as the nucleus which also received photon irradiation the reduced 
nuclear dose allowed not only survival of the cell but the ability to 
hypertrophy ajid divide when stimulated by T.S.H.
g a a r
The histological anatomy and physiological functions of the 
thyrotoxio follioular cell are outlined. The cell apex is important 
for hormone synthesis, the nucleus at the base of the cell is necessary 
for viability and reproduction# Eypothyroidism after iodine-131 
therapy is due to intense nuclear irradiation.
The decay of iodine-125 is described in deta3.1. Tlie major 
emissions are very low energy electrons and when iodine-125 is stored 
in the oolloid it causes intense irradiation of the apex (functional 
gone) and leaves tlie nucleus (reproductive zone) relatively unscathed 
(figure A9)* Hadiobiologioal experiments in animals have shown that 
iodine-125 does in fact diminish cell function preferentially and cell 
divisional capacity is not impaired to the same extent.
40
Section B
Treatment Of Thyrotoxicosis With Iodine-125 
Clinical Trials
Chapter I
Treatment Of Thyrotoxlcoele With Iodine-125 
Pilot Study and Dosimetry
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Introduction
Iodine-131, because of the mutually unsolvabl© problems of the 
cumulative incidence of hypothyroidism and the slow rate of symptomatic 
control, is not the ideal radionuclide for the treatment of thyro- 
to3doosls (Section A, Chapter l). The physical decay of iodine-125 
with its rich spectrum of low energy electrons raises the possibility 
that this radioisotope might partially overcome both of the deficiencies 
of iodine-131* The worlcing hypothesis that iodine-125 does pre­
ferentially reduce thyroid cell function without causing cellular death 
or sterilisation has been confirmed by animal experiments (Section A, 
Chapter II)* Limited trials in thyrotoxio patients were undertaken to 
assess whether radiobiological differences would be of clinical benefit 
as had been proposed by Greig (1968)0
Pilot Study
Once permission to prescribe therapeutic doses of iodine-125 had 
been obtained from the Isotope Advisory Panel of the Medical Research 
Council, the first important factor to decide was the dose range which 
should be used in the preliminaa?y studies* The lovf energy electronic 
emissions produce an intense irradiation of the colloid cell interface, 
but the rapid fall off in radiation across the cell when iodine-125 is 
used means that the nucleus is subjected to a considerably reduced rad 
dose compared with an equivalent dose of iodine-131* Therefore two 
possible approaches had to be considered. Firstly small doses of 
iodine-125 could be prescribed to produce an apical cytoplasmic dose 
similar to that delivered by standard amounts of iodine-131, This 
would greatly reduce nuclear exposure. The alternative method was to 
use amounts of iodine-125 which would expose the nuclei of the 
follioular cells to the same dose rate as iodine-131. The latter 
technique was adopted for the following reason* If small doses of 
iodine-125 had not produced a clinical improvement the planning of
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subséquent studies would have been difficult* With the large doses 
the nuclear irradiation should produce results at least as good as 
standard amounts of iodine-131 and if they were found to be ineffective 
further trials could confidently be abandoned altogether since the 
total body radiation burden of larger doses would be prohibitive#
Using iodine-131 a fairly predictable response can be expected 
with a dose of 10,000 rads, at least 50 pon cent of the patients 
recovering in about 3 montlis# A decision was made to commence the 
trial with quantities of iodine-125 which would deposit this amount 
of radiation at 10 microns from the source (the distance of the nucleus 
from the colloid in the elongated thyrotoxio follioular coll). Since 
the nuclear dose is reduced by about 80 per cent with iodine-125 tlie 
original doses prescribed were the standard iodine-131 doses multiplied 
by a factor of 4*
Patients Studied
10 patients all over 60 years of age with confirmed thyrotoxicosis 
received large doses of iodine-125 (Table Bl). The average dose 
prescribed was 38.2 mOi and two patients received more than 50 mOi#
Tlie mean time for recovery was 8.5 weeks (8 had normal thyroid status 
both clinically and biochemically by 10 weeks) and all 10 were euthyroid 
within 20 weeks (Groig et al 1969). Tlie patients who received the 
largest doses, 56.0 mCi and 57.0 mCi, are still euthyroid after 37 and 
39 months respectively. Vfith iodine-131 a less satisfactory rate of 
control and recovery would have been expected and almost certainly at 
least 3 of the patients would have required re treatment.
The justification for the trials and for these dose schedules was, 
therefore, complete and the outstanding consistency of recovery 
suggested, thou^ did not prove, that part of the effect of iodine-125 
was indeed extranuclear. Hypothyroidism was predictable with these
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nuclear dose rates and it rapidly occurred in 3 of the 10 patients* 
Iodine-125 was, therefore, known to produce rapid clinical control of 
thyrotoxicosis hut it was then necessary using empirical dose schedules 
to prOBcrihe successively smaller amounts and by careful clinical 
assessment decide which produced the beet outcome* The pilot group 
received approximately 1,000 uGi per estimated gram of thyroid and 
this small group has grown by the accretion of 7 additional patients 
who have received more than 750 nOi per gram of thyroid* The trials 
were extended using progressively smaller doses per gram of thyroid 
(Greig et al 1971, MoDougall et al 1970, MoDougall et al 1971a, 1971h). 
There are now in addition to the group of 17 patients who have received 
the largest therapy doses, 6 other treatment groups who have been given 
651 to 750 uCi, 551 to 650 uCi, 451 to 550 uOi, 351 to 450 uCi, 251 to 
350 uCi and 15I to 250 uOi per gram of thyroid. Details of the patients 
in these groups are comprehensively discussed in Section B, Chapter XI.
Of ^ lyroid Folliculaa? Cell 
The ^  particles emitted by iodine-131 travel distances which are 
considerably greater than the size of individual follicular cells or 
even thyroid follicles. With this radionuclide the Irradiation of 
the whole gland is fairly uniform and the mean gland dose wliioh is the 
figure used for therapy is an accurate indicator of the irradiation of 
all parts v/ithin the gland. With iodine-125 this is not the case. 
Photon emissions do irradiate the whole gland but their contribution is 
small. Because of the low energies of the electrons (especially those 
between 0.2 Kev and 3*7 Kev) there is no cross fire between follicles 
and ’iiie electron dose at any point in a follicle Is duo solely to the 
activity of that follicle. Tlie majority of the electrons have ranges 
of less than 1 micron thus the dose at the nuclear level of the 
follicular cell is only a fraction of tlie dose at the colloid cell
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interface even when the photon component is added to the important 
eleotroni-C component. Total thyroid rad dose is, therefore,meaning­
less with reference to iodine-125 therapy, and the important dose rates 
are at oolloid cell interface and at the follicular cell nucleus (lO 
microns from colloid oell interface). Gillespie et al (1970) using 
models have calculated the rad does from 1 raOi iodine-125 per day at 
these levels. There are certain factors which alter the doee rates, 
the first being the relative proportions of the radionuclide in the 
follicular oell and in the colloid. In general more than $0 per cent 
of stable iodine is in the oolloid and 10 per cent in the cells (hadler 
et al 1962) the same obtains 1 for iodine-125* If 100 per cent of the 
iodine-125 is in the colloid the nuclear dose rate will be less than if 
10 per cent of the radionuclide remains in the follioular cells. For 
calculations in this thesis it has been accepted that 10 per cent of 
the iodine-125 is in the cell and tlius the nuclear rad dose quoted may 
be slightly exagerrated. The dose rate also varies depending on the 
gland size and on the fraction of the gland which is colloid. Rad 
calculations have been based on the olini.cal estimation of gland mass 
and in each patient the colloid fraction has been taken as 15 per cent. 
Using the general calculations of Gillespie et al ( 1970) which have been 
expanded to include glands weighing from 20 gram to 100 gram (Table B2) 
it is possible to construct graphs for the dose rate per mOi iodine- 
125 per day at different distances from the colloid in thyroid glands 
of different masses. Figure Bl shows the rad doses that ono mOi 
would produce at the colloid cell interface and at one and 10 microns 
from the apical membrane assuming in each case that 90 per cent of the 
iod3.ne-125 is in the colloid and 10 per cent in the follicular cell 
and that the colloid fraction is 15 per cent. Using the reading in
rads per day per mOi iodine-125 from the desired graph it is possible 
to calculated the total rad dose at any level in the cell in any patient
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from the formula
Rad Dose = R % Administered Dose (mOi) x Percentage thyroid Uptake of
Dose X To (l)
100
V^here R ss Reading from graph (as described)
lUe a Effective half life of iodine-125 in thyroid
% e  factors in the calculation of (r) which are difficult if not
impossible to estimate have been discussed* ®he administered dose is
an exact measurement In this equation but the percentage uptake of
iodine-125 into the thyroid is difficult to obtain* Iodine-125 emits
photons in the 27 to 35 Kev range and although there is a hi^ relative
photon energy ratio which maJces the nuclide suitable for. counting
(Riocabona 19 5^* Den Porath et al 1$66) absorption of radiation in
glands of different sizes must be taken into account. Methods which
have been designed to overcome this problem are rotating detectors
(Gillespie and Eraser 1972) and application of the inverse square law
principle (Rollo 1971) hut because of the problem of exact measurement
with iodine-125 the 24 hour uptake of the diagnostic tracer dose of
iôdine-131 was accepted to be representative of the uptake of the
therapy dose* %is may hold true for some patients but fluctuations
in uptalce over short periods of time are knovm to occur (Silver I968,
Childs and Holbrook 1969)# final measurement of this formula* the
effective half life of the iodine-125* is subject to the great
individual Variation. For the basis of the calculations an effective
half life of 15 days has been used. This result was obtained from the
formula
Te %  ^
Where %  » Biological half life wliioh is on average 20 days 
in a thyrotoxic patient (Rhodes and Wagner 1971)
'fp « Physical half life (60 days)
4 patients had serial whole body counts before and at intervals 
after iodine-125 therapy in an effort to calculate the effective half
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life. Becaiise of the difficulties in counting iodine-125 diecucsed 
above it was impossible to obtain a smooth ctirve of radioactive fall 
off with time. Invariably the whole body iodine-125 radioactive 
reading immediately after therapy was lower than the result 3 or 4 
days later. The reason for this is that for the first estimation 
the radionuclide was in the gastrointestinal canal shielded by 
several centimetres of subcutaneous tissue whereas for the latter 
reading the vast majority of the material was concentrated super­
ficially in the thyroid. Using this direct but inaccurate method 
the effective half life ranged from about 7 to 20 days. The same 
problem was encountered by Wemer et al (1970) who found the range 
from 6 to 27 days. To overcome the counting difficulties 5 patients 
were given a 50 uCi tracer of iodine-131 simultaneously with the 
therapy dose of iodine-125# The 364 Kev photons from iodine-131 could 
then be accurately counted irrespective of the depth of the isotope in 
the body. Since both radionuclides were being handled simultaneously 
in the body it is fair to conclude that the biological half lives would 
be the same. ITsing this justifiable assumption the following series 
of steps wore undertalcen. The effective half life of iodine-131 in
the patient was calculated by serial whole body measurements making 
standard corrections for the background radiation and fall in radio­
activity in a phantom. Once this was obtained the biological half 
life was calculated from formula (&). With this result the effective 
half life of iodine-125 was obtained from the same equation but 
substituting the physical half life of 60 days. Table B3 shows the 
effective half life of iodine-125 in 4 patients by direct measurement 
and 5 patients by this indirect technique. The effective half lifes 
by the latter approach show a small variation (25 to 33 days). Recently 
the effective half life of iodine-125 in the thyroids of seven euthyroid 
radiation workers accidently exposed to iodine-125 vapour was calculated
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to be 41 ” 2 days (Bordell et al 1972)#
Prom the above argument the result of 15 days may be used as a 
working average figure but in some patients the effective half life 
may be twioe as long and if the effective half life is doubled the 
rad dose to the patient is doubled. Table B4 shows the mean results 
obtained by simple but tedious application of equation (l) in the 
calculation of the rad dose at the colloid cell interface and at the 
level of the nucleus in the follicular cells. Por each patient the 
uptake of isotope, the dose prescribed, and the reading from the graph 
depending on gland siae have been multiplied together and the total 
multiplied by I5. The average results and standard error have been 
calculated in all the patients who became euthyroid and hypothyroid 
or who remained thyrotoxic after iodine-125# The mean results in 
the 7 treatment groups are also shown# In ^ brackets are the results 
if the mean effective half life is 30 days this gives the greatest 
possible mean rad dose which could occur* Although it is agreed that 
some patients would have tills amount of radiation the smaller results 
are most certainly a more accurate guide to the whole group of patients# 
Details of the total group of iodine-125 treated patients will be given 
in Section B, Chapter II,
Summary
A pilot study with large doses of iodine-125 in the treatment of 
thyrotoxicosis was extremely successful and justified extension of the 
trials with smaller therapy doses.
Calculation of the rad dose to various levels of the thyrotoxic 
follicular cell involves the use of several assumptions which are 
hoped to be valid when large numbers of patients are involved.
Section B
rPter II
Treatment Of %yrotoxioosic With Iodine-125 s 
3?ull Scale Clinical Trial
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Introduction
The clinical outcome of 265 patients treated with iodine-125 at 
the Department of Huclear Medicine of the Royal Infirmary, Glasgow, 
from the commencement of the pilot study on 26tii July, 1968, up until 
the first of October, 1971» ic described in detail. Ho patient 
treated within tliis group has been excluded. The length of follow up 
in patients treated after the first of October has been too short for 
assessment.
Selection of Patients for Iodine-125 Therapy 
Since the rate of symptomatic response to iodine-125 was unknown, 
all of the patients treated at the start of the trial were reviewed 
frequently. There was, therefore, a tendency to select patients who 
lived within a radius of about 30 miles of the Royal Infismary. All 
patients treated with iodine-125, Irrespective of their source of 
referral, continued to attend clinics at the Department of Ruclear 
Medicine; a small porportion of the 70 patients who were referred 
from other centres were also supervised a,t their "parent" hospital.
For two reasons a definitive policy was adopted to treat patients 
with small diffuse thyroid glands. Firstly estimation of the gland 
siae by palpation v;as simpler and secondly any nodules arising after 
therapy would be detected more easily. After considerably experience 
had been gained a small number of patients with multinodular (14) or 
single toxic nodules (2) were treated with iodine-125# Therapy was 
restricted, as far as possible, to those aged #  year or older.
Pre-Therapy Diagnosis of Thyrotoxicosis 
Patients referred for radioiodine therapy usually were already 
diagnosed as thyrotoxic with confirmatory laboratory evidence of the 
diagnosis. If the only documented data was biochemical (protein 
bound iodine-127) the percentage thyj^ oidal uptalce of a 5 uCi tracer 
dose of iodine-131 24 hours after administration was estimated to
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provide additional information* Tills result was available in 262 of 
the 265 patients before treatment wan prescribed, the average result 
was 64 per cent (normal range 20 per cent to 50 per cent)* The 
protein bound iodine-127 was also estimated in 137 patients (51.2 per 
cent of the total group) the mean result was 12.9 ug per 100 mis. and 
the range 6.8 to 20.0 ug per 100 mis. (normal range 4#0 to 8.0 ug per 
100 mis.).
Discussion V/ith Patient 
Before treatment was prescribed either Dr. W.H. Orel g or I 
interviewed each of the patients. The severity of the disease in 
each individual was assessed and the beginning of an important rapport 
established. Time was talcen to explain the nature of the therapy, 
its lack of side effects and the probable rate of recovery* The 
possible need for re treatment or occurrence of thyroid failure in the 
future were introduced to emi^ hasiae the importance of intermittent 
review after therapy. All patients still in the fertile age range 
Yfero advised to take contraceptive precautions for one year from the 
time of treatment.
Admlni. strati on of Therapy Dose 
After calculation of the individual doses in the manner described 
before, the therapy doses were ordered from the Radiochemical Centre, 
Amersham. Therapy drinks were always prescribed on a Friday. 
Knowledgeable advice v/as sou^t about precautions to be adopted to 
safeguard radiation exposure and after detailed consideration it was 
deemed unnecessary to take special precautions about the disposal of 
radioactive excreta and most of #ie patients attended the Department 
of Nuclear Medicine for only a few minutes on an outpatient basis. 
Nevertheless strict attention was paid to the technique of administration 
care being talcen to avoid contamination.
51
Review Arran^menta After Tlierapy
Routine reviews of the patients were undertaken by only two 
phyeioians (Dr. ?/.R. Grelg and myself). Tliis was important not only 
in the assessment of the therapeutic response but also in the 
mai.nt©nano0 of each patient's morale especially at times when the rate 
of recovery did not meet his or her expectations* If any patient 
failed to keep a clinical appointment a new date was arranged for one 
week later.
The necessity for frequent reassessment has been discussed and 
almost every one of the first 50 patients returned at fortni^tly 
intervals until euthyroid; with greater experience in the pattern of 
recovery the frequency of follow up visits was reduced. , Patients were 
then reviewed routinely four weeks after the therapy dose and depending 
on the general condition of each individual the succeeding visits were 
planned accordingly* If there was no diminution in the thyrotoxic 
features reviews were planned more often so that any adjuvant therapy 
or re treatment could be introduced without delay. Patients who became 
euthyroid and remained so returned after progazessively longer intervals, 
two, three, four and six months. When a clinical suspicion of sub- 
thyroid!sm arose a sample of venous blood was withdrawn for estimation 
of serum protein bound iodine-127 and or serum thyroxine and review 
arranged one or two weeks later. With the îmowledge of the biochemical 
results a decision was reached whether or not to start life long 
replacement therapy. No attempt was made to wean patients off thyroxine 
once it had been started though two patients did stop it of their own 
accord. Even when hypothyroid,patients were well established on 
thyroxine therapy they have been reviewed at 6 monthly intervals.
52
!>•
*
eg
CM
M
CM
H
eg H
eg
«
eg
eg
#lA
I
m VO m iH VO t- VO# • * • *
eg H 00 r*{ COH rH M eg M eg r4 eg
lA
m
0r-l
I
g
OH
ÏH
o
§
s
1
I
43
's
I
IPi
(0
(g
%
00
3
eo
A IR
5
%
lA <y\ o 0\ M
lA
H
Ei
3
ON H
*S5j-cg
r'4
0
1
m  m
f
M
)W
a
%
sj-
UN VO c— R
I * 1 1 1 1
R @ R
Gland Bise Before Iodine-125
Gland Mass (G*) Number of Patients Per Gent of Total
25 53 20*0
30 58 21,9
35 20 7.6
40 62 23,4
45 5 1.9
50 51 19.2
Greater than 50 13 4.9
Not Noted 3 1,1
265 100,0
Patients Treated With Iodine-125 
Sex and Age Distribution
227 (85.7 per cent) of the treatment group are female and 38 are
male (14*3 per cent). The age distribution of the patients at the
time of treatment is shown in Table B5. The age range from 33 to 76
years includes 10 patients (3.8 per cent) who were under 40 years, 9
of these patients were either 38 or 39 year old. Almost three quarters
of the total group (73*3 per cent) were aged between 40 e^ id 59 years and
only three (l.l per cent) were 75 years of age or older.
Thyroid Gland Mass Before Treatment 
Estimation of the thyroid weights was made by palpation and 
expressed to the nearest 5 grams. Impalpable glands wore empirically 
accepted as weighing 25 grams and this was the lower end of the weight 
range, 75 grams was the heaviest. 72.5 per cent of the glands were 
estimated to weigh 40 gram or less. Details of the number and per­
centage of patients with glands of different masses are shown in Table 
B6. No record of gland mass was made in 3 of the patients (l.l per 
cent).
Bose of Iodine-125 (uOl) Administered Per Gram Thyroid
Each patient received a preselected dose of iodine-125 per estimated
gram of thyroid. The total administered dose was calculated from the 
formula
Administered Bose (mOi) » Desired uCi dose per gram x Thyroid mass (gram)
1,000
7 treatment groups received the following mean doses, 203.3 uCi 
per gram (range 15I-250), 309*6 uCl per gram (range 251~350), 399*1 uOi
per gram (range 351-450), 498*1 uOi per gram (range 451-550), 600*9 uOi
per gram (range 551-660), 692.6 uOl per gram (range 651-750) and 995*3
uOi per gram (greater than 750). Most of the patients in each group
received a "whole number" dose, 200 uGi, 300 uOi etc. per gram. The
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Table B 7
Number and Percentage of Patients who Received Different 
Admini stored Doses of Iodine-125 Per Gram Thyroid
Dose Range (uOi/G) Mean Nimber of Patients Percentage <
Less than I50 2 0.8
151 - 250 203.3 45 17.0
251 - 350 309.6 61 23.0
351 - 450 399,1 48 18.1
451 - 550 498.1 32 12.1
551 - 650 600.9 35 13.2
651 - 750 692.6 22 8.3
Greater than
750 995.3 17 6.4
Not Noted 3
265
1.1
100.0
Table B 8 
Initial Boses Of Iodlne-125
Dose (inOi) Humber of Patients Percentage 1
5 or less 15 5.7
6 - 1 0 65 24.5
11 - 15 76 28.7
16 - 20 55 20.7
21 - 25 22 8.3
26 - 30 25 9.4
31 - 35 0 0
36 — 40 4 1.5
41 - 45 0 0
46 - 50 X 0.4
Greater than 50 2 0.8
265 100.0
Table B 9 
Total Results After lodi&e-lgg Therapy 
Status Number of Patients Per Gent of Total
Euthyroid. 179 67.5
Hypothyroid 42 15*9
Thyrotoxic 33 12.5
Equivocal a 3.0
Not Followed 3 1.1
Total 265 100.0
Table B 10
Outcome Following! Iodine-125 Relation to Sex of Patient
Females Males
Number Percentage Number Percentage
Total 227 85.7 38 14.3
Euthyroid 149 64.8 30 79.0
Hypothyroid 39 17.2 3 7.9
Thyrotoxic 28 13.2 3 13.1
Equj.vooal 8 3.5
Not Followed 3 1.3
Mean Follow (months) 19.0 17.9
•i.%
Range (2-41) (3-36)
number in each treatment group and the percentage of the total group 
are shown in Figure B7* 2 patients received less than I50 uGi per
gram of thyroid and the dose per gram was not calculated in the 3 
patients whose gland siaes wore not estimated#
Initial Total Dose of Iqdlne-125 
The initial therapy doses calculated from the formula above varied 
in amount from 5.0 to 57*0 mOi. The number and percentage of patients 
treated with doses within a 5 mOi range are tabulated (b8). The range 
from 11.0 to 15.0 mOi was the most frequently used and 80.0 per cent of 
the patients received 20.0 mOi or less for the first therapy drink.
Results
Outcome in Total Treatment Group 
179 of the entire group of 265 patients are euthyroid (67*5 per 
cent), 42 (15*9 per cent) have become hypothyroid and 33 (l2.5 per cent) 
remain thyrotoxic (Table B9). 8 female patients (3.0 per cent) are
classified as "equivocal" since although they are olinioally euthyroid 
this status is not substantiated by laboratory results. Despite 
unceasing requests to attend for review 3 female patients (l.l per cent) 
did not do so.
Relation of Sex of Patient to Eventual Thyroid Status 
Table BIO records the percentage of male and female patients in 
these 5 outcome categories. 64-8 per cent of the females are euthyroid 
compared with 79*0 por cent of the males, the incidence of hypothyroidism 
in males (7*9 per cent) is lower than in females (17*2 per cent). An 
almost identical proportion of male and female patients are still thyro­
toxic. There is no statistioa]. difference in the length of follow up, 
the average time for females is I9.O - 9*3 months (range 2 to 41 months) 
and for males 17.9 - 8.3 months (range 3 to 36 months).
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Of the 179 olinioally euthyroid patients 149 are fema3.e (83*2 per 
oent) and 30 male (l6,8 per cent). Their average age at the time of 
the initial therapy was 52.0 years (range 33*0 to 76.0 years) and an 
average dose of 442.2 - 192.8 uCi iodine-125 v/as prescribed per gram 
of thyroid (range 200 to 1,120 uOi per gram) and the average first 
dose was 16.9 - 9*43 (range 5.0 to 57*0 mCi). Retrospective 
calculations of the rad dose at the nuclear and apical levels of the 
follicular cells were 4,500 and 15,000 respectively (approximate).
These patients have been under supervision for 19*7 - 8.7 months 
(range 3 to 41 months).
Hypothyroid Patients (Table Bll)
42 patients of average age 52*7 years (range 38 to 69) have become 
hypothyroid at varying intervals of time after iodine-125 therapy. 39 
(92.9 per cent) are female and 3 (7.1 per cent) male. The mean
administered dose per gram of thyroid was 581*7 - 273*7 uCi (range 200 
to 1,600 uCi per gram) and the mean initial therapy dose of 20.9 - 
8.23 mOi (range 6.0 to 40.0 mOi). These doses gave an average of 
approximately 6,000 rads to the follicular cell nuclei and 21,000 rads 
to the cell apices. The average length of follow up is 21.2 - 8.5 
months.
An average of 6.9 months (range 2 to 31 months) passed between the 
administration of the therapy dose and the onset of hypothyroidism. The 
cumulative percentage of patients who developed this complication and 
its time of onset are illustrated in Figure B2. 3 months after
therapy 28.6 per cent were already hypothyroid,at 6 months this had 
risen to 66.7 per cent and by 1 year to 88.1 per cent. 11.9 per cent 
of the hypothyroid patients (1.9 per cent of the total group) developed 
thyroid insufficiency more than 1 year after treatment.
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TIME OF ONSET OF HYPOTHYROIDISM 
AFTER THERAPY
lOOi
70
60-
TIME -  MONTHS
Belay in onse-fc of hypothyroiaiem in 42 patient® 
expresraerl as a peroentage of the total fproup 
against time in months*
2 of the 42 patients were given iodine««125 since they had relapsed 
after surgloal treatment of thyrotoxicosis* One patient although 
unduhitably clinically thyrotoxic before trea,tm.ent had completely normal 
results of thyroid fimotion (protein boimd iodine«127* 3*6 ug per 100 
mis; 24 hour uptalee of a tracer dose of iodine-131, 40 per oent and 48 
hour protein bound iodine-131, 0*18 por oent dose per litre). A 
fourth patient had a well substantiated history of hypothyroidism 
treated with thyroxine for several years before she developed thyro­
toxicosis. After iodine-125 therapy she promptly reverted to the 
hypothyroid state.
flxvrotoxio Patients (Table Bll)
3he 33 patients (12.5 per cent of total) v/ho are still thyrotoxic 
after iodine-125 (84.8 per oent females, 15*2 per cent male) were 52*4 
years of age at the time of therapy (range 40 to 75 years). fflae 
average dose prescribed per gram of thyroid was 303*1 ^ 126.2 uGi and 
the initial moan dose 10.7 ^ 4*4 mOi (rmige 5 to 20*0 mOi). The 
nuclear rad dose calculated in retrospect was about 3,000 rads and the 
apical dose about 10,000. Review has been undertaken for 10.2 - 7*1 
months on average (rm:ge 2 to 33 months), one patient followed for only 
2 months died from a cerebrovascular accident (Section B, Chapter III), 
but she was still thyrotoxic at the time of her demise.
In these three main outcome groups euthyroid, hypothyroid and 
thyrotoxic the doses administered per grain were significantly different 
(euthyroid/hypothyroid, P < 0.001s euthyroid/thyrotoxic, P < 0.001).
Ylhen the total doses prescribed were considered this level of 
significance was found between the thyrotoxic and euthyroid patients but 
the difference between hypothyroid and euthyroid patients was somewhat 
less (0.05 X- P> 0.025). There was no difference in the length of time 
euthyroid and hypothyroid patients have been under surveillance but the 
shorter follow up of the thyrotoxic patients was highly significant
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(p < 0*001) when oompared with both of the other groups*
Siquivocal Patients 
8 female patients all olinioally well were originally classified 
euthyroid, however, in 3, serum thyroxine and T*£î*H* levels suggested 
that they were in fact hypothyroid, the relevance of these findings 
will be discussed in Section C, Chapter I. In the remaining 5 patients 
the thyroxine levels were persistently elevated, though just above the 
upper limit of normal.
Outcome Related to of Patient at the Time of Treatment#i«,# i.wui# w i . . i . i i # w i m aiw tm
Table B12 shows the number and percentage of patients who are 
euthyroid, hypothyroid and tîiyrotoxic after therapy depending on their 
age at the time of treatment. Tiie smallest percentage of euthyroid 
patients are in the age groups 45 to 49 and 65 to 69, 58.2 per cent and
54.2 per cent respectively (Figure B3). In these groups a higher 
percentage of patients are still thyrotoxic (l8.2 per cent and 16.7 per 
cent) but in the latter group 25.0 per oent are also hypothyroid.
Relation of Gland Siae to Outcome
Tlae status after radioiodine therapy is related to the estimated 
v/ei£#it of the thyroid at the time of therapy (Table BI3). 64.6 per
cent with thyroid glands viei^ iing 40 gram or less a,re euthyroid; 75-3 
por cent of those with larger glands have a favourable outcome. The 
incidence of hypothyroidiom in those patients with small thyroids is
17.2 per cent oompmzed with 12.3 per cent in those with larger glands. 
Persistence of thyrotoxicosis after therapy is also more common in 
patients with thyroids weiring 40 groxA or less, 14.I per cent against
8.2 per cent. nevertheless, if the small number of patients whose 
glands were estimated to weigh exactly 45 gram, and those with thyroids 
of more than 50 gram as well as those whose gland siaes were not 
assessed are excluded, the fairly uniform distribution of euthyroid,
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hypothyroid and thyrotoxic patients is apparent#
Outcome Belated to Amonnt of Initial Therany Bose 
Prom ïahle BI4 it can be seen that most of the patients tvho remained 
thyrotoxic after iodine-125 were treated with small doses and persistance 
of toxicity decreases as the sise of the therapy dose increases# No 
patient who received an initial dose of more than 25*0 M3i is still 
thyrotoxic (Figure EI4)* 3he converse is not true for the hypothyroid 
patients? although there is a progressive rise in the proportion of 
patients who become subthyroid with larger therapy doses, tiiis relation­
ship only holds up to the dose range 26*0 mOi to 30 #0 mCi# Only one of 
7 patients who received more than 30#0 mOi has developed thyroid failure# 
'fhe doses associated with the best results æ:e the 11*0 to 15*0 mCi 
range (71*1 per cent euthyroid) and 16#0 to 20.0 mOi range (74*5 per 
cent euthyroid)#
Outopme Related to Initial Adaainistered
The 7 trea'toiont groups who were given from I5I to 250 uCi up to the 
doses greater than 750 uOi per gram of thyroid have already been defined# 
The patient information and outcomes in the 7 groups ai?o listed in Table
BI5 and BI6. The mean dose prescribed per gram in each group is
significantly different from every other group (P <C O.OOl)*
Group 1 (151-250 uOi per gram)
45 patients, 41 female and 4 male, received a mean dose of 203*3 
uOi per gram of thyroid, the mean initial dose per patient was 6.9 HK3i# 
57*8 are euthyroid, 8*9 per cent hypothyroid and 27*6 per cent remain 
thyrotoxic after a mean follow up period of 10#4 months# 4*4 per cent
of the patients are not allotted to one of these outcome groups and 2.2
per cent have not been traced. Tlie follicular cells have been 
subjected to approximately 2,000 and 7»000 rads at the nuclear and 
apical levels. 33*3 per cent and 13*3 per cent of patients have 
required second and third doses respectively reflecting the problem of
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persistant thyrotoxicosis.
Group 2 (251-350 uOi per gram)
A mean dose of 309*6 uCi per gram of tîiyroid was administered to 
61 patients of whom 54 are female. The Initial average dose was 11.7 
mCi. After 11.3 months of review 67*2 per cent are euthyroid hut 24*6 
per cent remain thyrotoxic. Only 4*9 per cent require substitution 
therapy with thyroxine. 26.2 per cent received a- second therapy dose 
and 4*9 P®r cent required a third. The rad doses calculated in 
retrospect were about 3,000 to the nuclei and 10,000 to the hormone 
synthesising fraction of the follicular cells.
Group 3 (range 351*450 uOi per gram thyroid)
48 patients (43 females and 5 males) who received an average initial 
dose of 16.6 raOi have been under review for 24*6 months. 87.5 per cent 
are euthyroid, 10.4 per cent hypothyroid and 2.1 per cent thyrotoxic.
29*2 per cent of this group have required re treatment. The dose rates
were approximately 4,000 and 13,000 rads.
Group 4 (range 451-550 uOi per gram thyroid)
27 females and 5 males received an average dose of 19*6 mOi iodine- 
125. This dose was calculated to administer a nuclear dose of 5,000 
rads and an apical dose of 16,000 rads. The follow up period is 25.3 
months and after this time 65.6 per cent are euthyroid and 22.9 per 
cent hypothyroid. An equal proportion, 6.3 per cent are thyrotoxic 
and equivocal. One therapy dose was sufficient for the treatment of 
75 per cent of the patients.
Group 5 (range 551-650 uGi per g3?am thyroid)
Of the 35 patients (30 females and 5 males) who received an average 
initial dose of 22.7 mCi and have been assessed over a period of 22.7 
months, 65*7 per cent are euthyroid, 31.4 per cent hypothyroid and the 
remainder (2.9 per cent) equivocal. An equal proportion of the group 
8.6 per cent required a second or third therapy dose. A nuclear rad
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IjlCrïïEE B 5
OUTCOME FOLLOWING 125; 
\xC\ DOSE PER GRAM.
EUTHYROID
HYPOTHYROID
30
10 THYROTOXIC
GROUP
Percentage of patients euthyr?oid, hypothyroid and thyrotoxic 
after iodine-125 therapy; relation to dose prescribed per 
gram of thyroid
Group 1 151 to 250 uOi
Group 2 251 to 350 uCi
Group 3 351 to 450 TiOi
Group 4 451 to 550 nOi
Group 5 551 to 650 uOi
Group 6 651 to 750 nOi
Group 7 over 750 uCi
0?able B 17 
Humber of Doses of Iodine-125 Adjidnistered 
Humber of Doses Humber of Patients Percentage of Dotal
1 187 70.6
2 58 21.9
3 18 6.8
4 1 0.4
5 1 0.4
265 100.1
jB :L8
Outcome Related to Humber of Dherany Brinks of lodine-XS^
One Dose 3ÎW 0 Dosea Dhree Dos$8
Humber of Patients 187 5 8 1 8
Males (per cent) 27 (I4.4f^ ) 7 (12.1/») 3 (16.7/»)
Females (per cent) 160 (85.6^ ) 51 (82.^) 15 (83.30)
Mean Age (Years) 52.2 52,6 52.6
Mean Dose (mOi) 17,6 14.4 12.6
Dose Per Gram (uGi) 474.5 373.1 383.3
lîutîîyroid (per cent) 132 {71*1/0) 36 (62.1?i) 11 (61.10)
Hypothyroid (per cent) 37 (]L9i:%&) 14 ( 6.9/) 1 { 5. #
Dhyrotoxio (per cent) 11 ( 5.9#) 17 (29.3S&) 3 (16.70)
%uivooal (per cent) 4  ( 2 , 1 # ) 1 (  1. 7/» ) ■ 3 (16.70)
Hot Followed (per cent) :) (]L.6(%6)
dose of 5,500 rads and apical dose of 20,000 rads has been calculated.
Group 6 (range 651-750 uCi per gram thyroid)
In this group an average dose of 24*5 mOi has been given to 22 
patients (l8 females and 4 male). The nuclear radiation dose was 
approximately 6,500 rads and at the cell apex 23,000 rads* 63*4 per 
cent are euthyroid 22.4 months after therapy, 31*8 per cent hypothyroid 
and the remainder have not been traced. A second treatment dose has
been required for 18.2 per cent.
Group 7 (greater than 750 uOi per gram thyroid)
An average dose of 32.2 mCi of iodine-125 has been administered to 
17 patients (14 female and 3 male). The nuclear rad dose has been 
calculated to be approximately 10,000 rads and the dose to the colloid- 
cell margin about 35*000 rads. 58*8 per cent are euthyroid and 29*4 
per cent hypotliyroid29*4 months after therapy. 88.2 per cent of tlie 
group responded to the initial therapy dose.
Figure B5 illustrates graphically the percentage of patients who 
are euthyroid, hypothyroid or thyrotoxic in each of the 7 groups.
Humber of Dheranv Doses Prescribed 
187 patients (70*6 per cent) Imve received 1 therapy dose, 58 
patients (21.9 per cent) 2 doses and 18 patients (6.8 per cent) have 
required 3 doses. 1 patient (0.4 per cent) has received a fourth 
and 1 (0.4 per cent) a fifth dose (Dable B17). Detailed information 
about these patients exolucUng the last 2 patients is shown in Table 
BI8* There is no difference in age in those who have required 1 or 
more treatment dose and the sex distribution is also similar. The 
patients who responded to the first therapy dose received a larger 
initial amount (17*6 mOi) than those who have required two (14*4 mOi) 
or three doses (12.6 mOi). The dose per gram of thyroid shows a 
similar pattern.
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Table B 19
Multiple Doses
Information about 58 Patients who had Two and 18 Patients 
\yho required Three Therapy Doses of Iodine-125
Two Doeee Three Doses
Humber of Patients 58 18
Female B 51 15
Moles 7 3
Mean First Dose (mOi) and Hange 14.4 (5-50) 12.6 (5-20)
Mean Second Dose (mOi) and Range 14*6 (4-30) 12.6 (5-6o)
Moan Third Dose (mOi) and Eange 17*2 (5-40)
Average Delay Between 1st and 2nd 5*5 (2-16) 4*6 (2-7 )
Drinic (months) and Range
Average Delay Detiveen 2nd and 3rd 5*1 (l-lO)
Drink (raontlis) and Range
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5*9 per cent of the patients treated with one dose are still 
thyrotoxic as are 29*3 per cent of those who have had two drinks and 
16.7 per cent of the three dose groups* The number of patients who 
have become hy^ iothyroid in the multiple dose groups are small but this 
may be a reflection of a shorter period of follow up since there was 
an average delay of 5*5 months between the prescription of first and 
second drinîcs and 4*6 months between second and third doses*
Table B19 lists the information about the doses prescribed on the 
second and third occasions. Of the 58 patients who received 2 doses,
49 had an identical second dose, 8 had a larger dose and 1 patient a 
smaller dose. All of the 18 patients who had 3 doses had the same 
amount on the second occasion but the third dose was tailored in an 
attempt to suit each individual and as a result 9 (50 per cent) 
received a larger and 3 (I6.3 per cent) a smaller dose.
Outcome Related to Lenfgth of Follow Up 
In Table B20 the outcome after iodine-125 has been related to the 
length of time (months) that patients have been under review. A 
patient who has become hypothyroid at 3 months but has been under review 
for 21 months is included in the 19 to 24 month group. The actual time 
of onset of thyroid failure after therapy has already been discussed.
In those who have been under review loss than 6 months, 48 per cent are 
euthyroid and 52 per cent remain thyrotoxic. The proportion who are 
thyrotoxic diminishes with the passage of time and only 3 are not 
controlled 18 months after the initial dose. From 7 to 36 raontlis after
treatment the percentage of hypothyroid patients remains fairly constant.
Adjuvant Anti thyroid Drugs after Iodine-125 Therapy 
31 patients (11.7 pen cent of the total group) required additional 
drug therapy, 17 of them (54*8 per cent) received oarbimuKole and 11 
(35*5 per cent) propranolol. These drugs were used in combination in 
two patients and one received potassium perchlorate because of previous
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sensitivity to oorMmaaolo (Table B2l). Only after drug therapy had 
been discontinued for 2 months was any patient classified as euthyroid, 
this has happened in 14 of the patients treated with carblmaaole and 8 
of those who were taking propranolol# Those patients who are clinically 
completely normal but taking a small dose of antithyroid drug therapy 
are still classified as Üiyrotoxic# 71 per cent of the group who 
required drug therapy had received loss than 450 uOi iodine-125 per 
gram of thyroid.
Outcome in Patients with Nodular Glands 
14 patients (12 females and 2 males) had raultinodular glands but 
after careful consideration they were treated with iodine-125# They 
were given a mean dose of 20.5 mOi or 463^5 uOi per gram of thyroid.
2 of these patients are hypothyroid and the remainder euthyroid after 
an average follow up of 24 months* (Table B22)
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PiaouBsion
patients were selected for iodine-125 therapy depending 
on a geographical basis and the anatomical type of thyroid they were 
overall representative of those referred to the Departîoent of Nuclear 
Medicine for radioiodine therapy. Despite the importance of frequent 
review visits there was no bias towards the selection of females and 
the ratio of female to male 85*7 to 14*3 is similar to the overall ratio 
in iodine-131 treated patients at this Department 82.8 to 17*2 (McGrirr 
et al 1964)* Only 10 of the total iodine-125 treatment group were 
under the age of 40 years at the time of therapy and this is in keeping 
with the policy of reserving radioiodine therapy until ttiis age is 
reached (McDougall et al 1971)* The main indication for this arbitrary 
time limit has been concern about the genetic hatsards of all radio­
nuclides of iodine and the younger patients treated with iodine-125 have 
been advised to talce contraceptive measures for at least 1 year* If no 
pregnancies arise there should be no increase in the burden of radio­
nuclide induced mutations passed on to future generations.
There was no doubt about the degree of toxicity of all of the 
patients. The average 24 hour uptake of a tracer dose of iodine-131 
was 64 por cent and the mean protein bound iodine-127, 12.5 por 100 
mis. There was no significant difference in the uptakes of tracer 
doses in the 7 groups of patients treated with different doses of 
iodine-125 (range 61.3 to 68.6 per cent). Only one patient who has 
previously been discussed had normal thyroid function tests, slie was 
clinically thyrotoxic and her thyroid may have been secreting 
inappropriately large amounts of triiodotlnyronine. Therefore, despite 
the selection of patients they did not have mild thyrotoxicosis.
The selection of patients with small diffuse glands was necessary 
to simplify estimation of thyroid maos. The difficulties and errors
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in this estimation are well loiovm but only two pliysicians, Dr# W#R# Greig 
and I were involved in this assessment# Marly in the trial an attempt 
was made using finely calibrated rectilinear scans to convert the 
measurements of area, height and width of lobes into an index of mass 
using the formulae of Eimahka and Larson (1955) and MyMll et ol (19&5)* 
Beoause of differenoes in the results obtained the simple palpatory 
method has been used throughout# Impalpable glands were empiricalljr 
gaged to weigh 25 gram (Melssner and Warren I969) this, of course, might 
exagerrate the weight of some (loohisiuki et al 1963) yet in other patients 
it may bo ©n underestimate. It is recognised that the mass of small 
glands is more often overestimated and the opposite is found in larger 
glands and a oonsoious effort was made to correct thj.s# This will be 
discussed at greater length in the section dealing with the outcome in 
relation to gland siae,
After similar lengths of follow up the final outcome in males (79 
per cent euthyroid) has been superior to that in females (64*8 per cent 
eutliyroid) # liiere was no intention to prescribe different treatment 
schedules in males and througlaout the 7 treatment groups (uGi per gram 
thyroid) the proportion of males and females is fairly constant# Less 
males became hypothyroid but surprisingly the proportion of males who 
received doses greater than 450 uGi per gram was slightly greater than 
in the lower dose schedules# This paradoxical combination of less 
hypothyroidism in patients who had received a slightly larger dose 
suggests that the males may be slightly more radioresistant# A 
similar conclusion does not hold true for iodine-131 therapy (Boling and 
Minlioffi 1961, Blalad and Mays 197&)# Most probably the small number of 
males treated (38) could account for tliis difference•<
A greater increase in the incidence of hypothyroidism after iodine- 
131 therapy has been found in elderly patients (Green and Wilson 1964) 
and this has been attributed to the rising frequency of hypothyroidism 
which occurs spontaneously with aging. Hone of the 8 patients aged
64
70 years or more became hypothyroid after iodine-125 treatment yet they 
received as large an average dose as any other group. (Plie lowest 
percentage of euthyroid patients were found in two groups of patients 
with age ranges of 45 to 49 years (58.2 per cent) and 65 to 69 years 
(54*2 per cent). An increased number of thyrotoxic patients in both 
of these groups partly accounted for the less satisfactory results but 
in the latter group 25 per cent (6 patients) have developed thyroid 
insufficiency. These 6 patients received laa?ge therapy doses and it 
cannot be concluded that their outcome was related to their age.
It is the general experience that iodine-131 is more often 
associated with hypothyroidism when the patient has a small gland, 
probably due to overestimation of the gland size and hence the therapy 
dose, Iodine-125 treated patients show a constant pattern of response 
through the 4 groups up to a gland mass of 40 grams (euthyroid 62.3 to
70.0 per cent, hypothyroid 14#5 to 20,0 per cent, thyrotoxic 10.0 to
16.1 per oont). Of the 5 patients whose thyroid glands were estimated 
to weigh exactly 45 gram, and the 13 patients with glands greater than 
50 gram not one has become hypothyroid. A clinical underestimation of 
the gland siae may have led to prescription of a smaller dose than 
intended but 16 of these 18 patients are euthyroid so if the dose 
prescription was too small it has certainly been enough to produce the 
desired effect. Because of the excellent results in these patients the 
outcome has been more favourable when the glands have been assessed to 
v/eigji more tl^ on 40 gram, 75.3 per cent are euthyroid compared with 64.6 
per cent with smaller glands. Overall the degree of correlation 
between the cliirical status after therapy and the gland sise justifies 
the conclusion that up to 40 grams clinical estimation of thyroid mass
is quite accurate and dose prescriptions valid.
Relating the outcome following iodine-125 treatment to the initial 
total dose shows tliat no patient treated with 5*0 mOi has become
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hypothyroid and that of all the patients who received doses up to 15 
mOi the incidence is still only 10 per cent. Despite the low hypo­
thyroid incidence the rate of control in the 5 mOi group has by stringent 
criteria been unsatisfactory since one third of the patients althou^i 
Improved are still clinically thyrotoxic. However, as tlie dose is 
increased control is more certain and in patients who have received
20.0 mOi or more it is virtually inevitable since only 1 out of 54 
patients remai.ns thyx'otoxio. With doses of this size the problem of 
hypothyroidism is evident and is similar to the expected incidence 2 
years after conventional doses of iodine-131 (about 30 per cent).
These amounts of iodine-125 are three or more times the standard dose 
of iodine-131 yet calculation of the nuclear rad dose gives a similar 
result in both Instances,
The most important index has been the clinical outcome In  relation 
to the dose of iodine-125 prescribed per gram of thyroid. In the lowest 
dose group (200 uGi per gram) more than one half of the patients are 
euthyroid and 8.9 per cent have actually had sufficient thyroid 
destruction to make them hypothyroid. The proportion of hypothyroid 
patients has remained at about this level up to doses of 450 uGi per 
gram but yet through this dose range the number of persistently thyro­
toxic patients decrease and hence the proportion of euthyroid patients 
is larger. For the best results at 24 months there appears to be a 
oritioal dose range of 350 to 450 uGi per gram thyroid, the group 
incorporates the highest number of euthyroid patients a very low 
failure rate and an acceptable number of hypotliyroid patients. With 
smaller doses a3.though the hypothyroid problem can be slightly reduced 
there is a slower rate of control ; using larger doses hypothyroidism 
is a problem.
The nuclear rad dose in this best treatment group has been 
approximately 3,500 to 4,000 rads. If this had been subjected by
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iodine-131 the majority of the patients would have required adjuvant 
drug therapy because of the slow rate of control (Smith and Wilson 1967)* 
Second doses would also have been required in up to 60 per oent of the 
group* More than 70 per cent of the patients treated with iodine-125 
responded satisfactorily to 1 therapeutic drinlc and only 12*5 per cent 
were given anti thyroid drugs* From personal discussion with Smith 
(1972) the antithyroid drugs were prescribed to iodine-125 treated 
patients earlier than would have been the case with low dose iodine-131 
treated patients* Overall, therefore, the difference in outcome proves 
that the two radionuclides are not working in the same way* The most 
likely explanation is that the intense irradiation of the Important 
hormone synthesising segment has reduced thyaroid hyperfunotion and the 
low dose to the nuclei has prevented thyroid cell failure*
Additional evidence of the difference in action of these radio­
nuclides is idle average approximate rad dose (4,000 rads) to the 
follicular nuclei in the 179 patients who have become euthyroid* Such 
a low dose would not produce unifom success if delivered by iodine-131* 
The same applies in the patients who have become subthyroid* Thyroid 
failure has resulted from a mean nuclear dose of 6,000 rad mid this 
would certainly not occur with iodine-131 2 years after therapy thou#i 
it would at a later date* It is, therefore, possible that the intense 
irradiation of the cell membrane not only reduces function but if great 
enou^ will cause cell death.
In patients who have received different dose regimes of iodine-125 
in excess of 550 uOi per gram thyroid the proportion of hypothyroid 
patients has remained constant around 30 per cent. This constant 
result has been obtained by a considerable variation in nuclear rad 
doses and it Is suggested that the nuclear and apical doses may combine 
in producing sterilisation or death of the cells* With these larger 
doses the rate of control (average 8.5 weeks in the pilot group and 14
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weeks for the first 50 patients) of the disease is considerably better 
than with iodine-131* Since both produce the same hypothyroid 
incidence which in the case of iodine-131 is due to nuclear damage the 
iodine-125 must also be reducing cellular secretory function. This 
difference is still apparent with the smaller therapy doses which have 
been calculated to deliver 2,000 rad to the nuclei. Recent trials 
with iodine-131 (1,750 rads) have necessitated prescription of anti­
thyroid drugs to 80 per cent of patients for as long as 2 years (Smith 
1972)* Only 4 out of 45 patients in the lovmst iodine-125 treatment 
group required additional antithsToid drugs and more than 50 per cent 
required only one therapy dose. When anti thyroid drugs are used there 
is an impression that smaller doses are required, this has also been 
described by Lowitus et al (1971b).
Iodine-131 therapy for nodular glands is associated with a lower 
incidence of hypothyroidism and often the need to prescribe larger 
therapy doses to obtain the same results as in patients with diffuse 
glands (Silver I968). It is, therefore, surprising that not one of 
the 14 patients with a nodular thyroid has remained thyrotoxic and the 
percentage hypothyroid (14*3 per cent) ?/as similar to the total 
treatment group. It is difficult to explain this difference but the 
long half life of iodine-125 may be important. As overactive nodules 
have responded to treatment other relatively less active regions of 
the gland may take up sufficient radionuclide to be treated. This 
would be akin to giving small fractionated doses of iodine-131 over a 
prolonged period.
Hypothyroidism may follow iodine-125 treatment, when it occurs it 
usually does so soon after therapy, 88 per cent within the first 12 
months. Because of the progressively smaller numbers of patients 
who have been under review for more than 2 and 3 years it has not been 
possible to calculate the progressive proportion of hypothyroid patients
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by the method outlined by 33eling and Binhorn (1961). But by simply 
showing the percentage hypothyroid in groups who have been under review 
for successive 6 month periods up to 42 months there has been a slight 
cumulative increase. Hone of the 4 patients who have attended longest 
have become subtîiyroid. The therapy doses prescribed to patients who 
became hypothyroid tended to be larger than those associated either 
with a favourable outcome or failure to control the disease (O’able Bll) 
and the nuclear and apical rad doses were also greater.
In view of tlie current tendency to favour anti thyroid drugs and 
small doses of radioiodine it is conceivable that with low doses of 
iodine-125 (5 mOi or less) hypothyroidism could be completely avoided 
but adjuvant drugs nd.ght be essential. This is not the ideal solution 
and the aim tliroughout these olinical trials has been to find by 
empirical means the dose or doses which would produce the best clinical 
results vdthout the need for other therapy*
Since the introduction of iodine-125 therapy (Greig et al 3
other groups of investigators have gained limited experience with this 
radionuclide. Wemer and his colleagues (1970) have treated two series 
of thyrotoxic patients in different countries. 6 patients received 
treatment in Hew York and 7 in Amsterdam and although the mean dose 
for each group was the same (lO.O mOi) the initial clinioal response 
was quite dissimilar* 5 of the patients in Hew York became hypothyroid 
whereas non© of the Amsterdam group developed this complication. This 
paradoxical difference was tentatively explained on the basis that the 
two populations had iodide pools of different sizes. The Hew York 
patients were considered to be iodine replete whereas the Amsterdam 
patients were relatively iodine deficient (Wiener 1971, 1972). In 
the experimental animal iodine deficiency has two important effects in 
relation to the radiobiologioal action of radioiodine, in particular 
iodine-125. Firstly the follicular cell becomes elongated and secondly
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the up t alee of radionuclide is increased* Vickej^ y and Williams (1971) 
have shown that the net result of those alterations considerably 
reduces the nuclear irradiation from a colloidal source of iodine-125* 
Although it is not known it is possible that iodine defioienoy produces 
a further incremental increase in the length of the already elongated 
thyrotoxic cell* If this hypothesis is oorrect iodine defioienoy 
should theoretically protect against hypothyroidism and an excessive 
iodine pool mi^t increase the probability of subthyroidism following 
iodine-125# On© method of proving or disproving this theory would be 
to measure the absolute iodine uptalee and retrospectively compare the 
results in those patients who remained euthyroid with those who became 
hypothyroid*
Binoo their original communication (Wemer et al 1970), however, 
it is relevant to note that 3 of the 5 patients who were hypothyroid 
have reverted to normal thyroid status (Werner and Jolinson 1971)# The 
resumption of normal thyroid function in 3 patients after a period of 
post iodine-125 hypothyroidism is of interest* It suggests that 
enhanced viability of the cells has been present leading to compensatory 
hypertrophy or hyperplasia resulting from increased pituitary T.B.H. 
secretion* Thus overall on3.y 2 out of 13 patients remain hypothyroid 
(15.4 per cent). .^Phese investigators have also treated 18 patients 
with smaller doses of iodine-125 (50 per cent of original dose) and
thyroid insufficiency has arisen in 1 patient (5*5 per cent).
I have not encountered any patient who once hypothyroid was able 
to discontinue thyroxine. Ho attempt was made to stop tliis treatment 
but two patients did so without medical advice. One rapidly became 
hypothyroid again and has restarted thyroxine, the other patient 
although well enou^ to continue at work is mildly hypothyroid with a
low thyroxin© and elevated serum T.S.H.
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Lewitus (1969) prescribed even smaller doses of iodine-125 (2*75 
mOi) in the first 4 patients he treated* Their rapid clinioal 
improvement, all 4 were euthyroid by 14 weeks, was attributed to the 
intense radiation to the hormone synthesising apparatus and he believed 
that further clinical trials were justified. Thirty patients received 
doses ranging from 1 to 3*5 mOi (Lewitus et al 1970) end subjective 
improvement occurred in 95 per cent within 6 weeks and none of the 
patients became hypothyroid after a follow up period from 3 months to 
1 year (one patient treated with this dose regime had a large thyroid, 
despite a nuclear dose of only 250 rads the outcome was reported as 
fair). An additional benefit of such low doses is the reduction in 
total body radiation to about 1 rad.* V/ith the extension of these low 
dose trials over a longer period of follow up Lewitus et al ( 1971a) 
found that the overall rate of control was unfavourable* 0iey found 
that 20 per cent of patients who had been euthyroid both by olinical 
and laboratory indices relapsed. They considered that their original 
doses had been too low and because of tills liave advocated two 
alternative approaches. Firstly that the administered dose of iodine- 
125 be increased to the range of 4 mOi to 6 mOi or secondly that a 
combination of iodine-125 and iodine-131 be prescribed together. Using 
the first approach 10 patients were treated witîi an average dose of 5 
ïï^ i and 6 (60 per cent) responded satisfactorily (Levdtus et al 1971b). 
Following the latter suggestion they have treated 40 patients with a 
mixture of approximately 50 per cent iodine-125 and 50 per cent iodine- 
131 (mean doses 3,0 mOi and 3*8 mOi respectively). Of these patients 
36 (90 per cent) ore euthyroid, 1 (2.5 per cent) has failed to respond 
and 3 (7*5 per cent) have become hypothyroid. Despite the excellence 
of these results which also includes rapidity of control the criticism 
that Iodine-131 has been employed must be levelled. Even with the 
doses of iodine-131 employed a cumulative incidence of hypothyroidism 
must be expected in the future* Proof of this is the 19 per cent
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incidence found by Lowe et al (1971) 2 years after 2.5 ®0i doses of 
iodine-131.
Siemsen (l97l) in an unpublished report has prescribed therapeutic 
doses of iodine-125 based on the clinioal experiences of Greig et al 
(1970) and McDougall et al (l97ü). 40 of 80 patients who received
100 uCi per gram thyroid responded poorly and he has abandoned this 
dose raoge. #ien tho dose was increased to 200 uCi per gram three 
quarters of a group of 60 patients became euthyroid, 5 per oent hypo­
thyroid and the remainder are still uncontrolled. There is no 
information etbout the length of follow up in these patients.
From the detailed results in this thesis and from information from 
other centres a pattern of response is emerging to different therapy 
doses of iodine-125 and despite various treatment schedules a consistency 
is noted. Small therapy doses 100 uCi per gram or total doses of 1 to
3,5 mOi do cause c3,inical improvement but a totally satisfactory outcome
is obtained in only about 50 per cent of patients. The remainder 
either remain unoured or relapse after a partial remission. Hypo­
thyroidism is virtually not encountered. Increasing the dose to 200 
uOi to 300 uCi per grain (about 5 to 10 mCi) the rate of recovery is 
hastened and about 75 por cent of patients will become euthyroid without 
a significant incidence of hypothyroidism. Ho other investigators have 
prescribed larger treatment doses but by presoribing about 400 uCi per 
gram thyroid the speed mid certainty of control of the disease are 
enhanced, however, about 10 per cent are hypothyroid after 2 years.
Tliere are a few patients who despite receiving a small dose 
uno3{pectedly develop thyroid insufficiency because of the long physical 
half life of iodlne-125 a small increase in the biological turnover of 
the isotope can considerably increase iiie radiation in these patients 
and this may be the reason. In others the thyroid cells may be
exquisitely radiosensitivo. There appears to date no way of
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anticipating or preventing this complication but theoretically if an 
index of the amount thyroid cell destruction could be obtained most 
of the Iodine-125 could bo discharged from the thyroid and prevented 
from re-entering it by antithyroid drugs.
One unsettled question is whether the nuclear radiation in the 
hypothyroid patients has been small enou# to allow cellular 
regeneration. Werner and Johnson (l97l) have described this but it 
has not been seen in tirls study althou^ substitution therapy was not 
routinely discontinued. The patients who ore most liable to recover 
from hypothyroidism are those who received small therapy doses but in 
vievf of the possibility of unrestrained cell growth in response to 
elevated T.S.H* levels the policy of continuing the substitution therapy 
is justified. Analogous with this suggestion is the possibility that 
euthyroid patients may relapse if the follicular cells are capable of 
regeneration. Early relapse has been described by Lewitus et al 
(1971b) but in this series no patient has been unequivocally euthyroid, 
after iodine-125, then sufferred a relapse.
Iodine-125 is effective in the treatment of thyrotoxicosis. A very 
rapid certain cure is obtained with total doses of 20.0 mOi or 
individually calculated doses greater than 550 uOi per gram of thyroid. 
Despite a lower nuclear rad dose the problem of hypothyroidism equals 
that from standard iodine-131 therapy. Within the dose range 350 to 
450 uGi per gram a,lmost 90 per cent of patients are euthyroid 2 years 
after therapy. Doses of this magnitude or less cause very little 
thyroid failure.
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Section  ^B
Chapter III
Assessment of Real and Potential Side Effects Arising from 
Thyroidal and Extrathyxoidal Radiations of Iodine-125
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Introduotion
ïh© problems of delo,yed control and the cmiilafcive incidence of 
hypothyroidism apart, side effects from iodine**'131 treatment are 
relatively imcoramon (Section A, Chapter l). It is, therefore, 
essential that iodine-125 is as benign in this respect; better 
therapeutic results cannot justifiably be obtained In the face of 
additional complications* She potential complications and problems 
which have arisen in iodine-125 treated patients are discussed imder 
6 headings; (l) immediate side effects of iodine-125 (2) thyroidal 
complications (3) effects of iodine-125 on haemopoietic tissues (4) 
extrathyroidal radiation effects (5) alteration in the course of 
infiltrative ophthalmopathy and (6) incidental complications. Within 
these sections are details of clinical problems as well as formal 
studies of morphological alterations in circulating lymphocytes and 
inve8tigatione of parathyroid function.
(l) Immediate Side Bffoots
A 64 year old female who had previously received 2 therapy doses 
of iodine-125 without 111 effect was quite ill vdth vomiting several 
hours after a third therapy dose. Retrospective estimation of the 
thyroid uptake of iodine-125 as well as serum protein bound iodine-125 
showed that she had absorbed at least 80 per cent of the dose# Prompt 
control of her disease confirmed this estimation. Most probably the 
symptoms were not directly related to the therapeutic drink since the 
patient had previously received two doses of similar amount with no ill 
effect. ïhe remainder of the patients were singularly free of reactions.
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Patienta with Pain Over Thyroid Region After Iodine-125 Dherapy 
Boae Administered and Eventual Outopme
O?otal Pose of uCi per Gram Clinical
Patient Age Iodine-125 Thyroid Thyroiditis Outcome
Female 65 30 1,200 Present Ibypothyroid
Female 51 20 400 Present Fbithyroid
Female 55 24 600 Present Hypothyroid
Female 41 20 400 Absent Euthyroid
Female 51 15 500 Absent Euthyroid
Female 61 10 400 Absent Euthyroid
Table B 24
.Amomts of Iodlne-125 Persisting in the Body of 4 
Patiente Treated 10. 12, 36 and 43 Months Befoi^ ehand
Pose Prescribed Amoimt in Body Time After Th'
(months)
10 
12 
36 
43
Sex Ago (Years) (mOi) (uGi)
1 F 53 7.5 i 7.5 0.6
2 ? 60 5.0 0.01
3 F 47 20.0 1.1
4 F 68 57.0 0.8
(2 ) SssaM sl.oasiââs3S-«Ba 
(a) 4onte
No patient developed thyroid crisis and there was no apparent 
worsening of the disease following treatment with iodine-125. Tlmt 
thyroid crisis does occur aftoD? iodine-131 therapy has recently been 
proven forcibly, two elderly patients treated in our Department with 
iodine-131 within the last year suoooumbed with intractable thyroid 
crisis despite the vigorous institution of anti thyroid drugs, beta 
adrenergic blocking drugs and inorganic iodine. Three female patients 
who complained of pain in the thyroid shortly after treatment with 
iodino-125 did have objective evideno© of radiation thyroiditis (Table 
B23). üOwo of them beoaaie liypotliyroid at 3 and 8 months respectively 
after treatment, 'Three other female patients reported soreness in 
the throat on swallowing but there was no clinical suggestion of 
thyroiditis and in each case the outcome has been favourable. In the 
latter g)^ oup of patients the symptom whs probably not due to iodine-125, 
however, the prompt onset of thyroid failure in 2 of the 3 patients 
with thyroid tenderness tends to incriminate the therapy in the 
production of thyroiditis and subthyroldisra. This sequence of events 
is lcno\m to occur with iodine-131 therapy (Schwarta 197S))*
(b) Chrpnio
The important potential hazard of thyroid oar'oinoma arising in 
patients treated with iodine-125 is discussed in Section 0, Chapter I, 
To date no patient who had a diffusely enlarged thyroid has developed 
thyroid nodules and none has required surgical exploration of the neck.
Van Middlesworth (1972) has drawn attention to a possible 
environmental hazfard from patients treated with iodine-125* In 
experimental animals he and hJ.s co-workers (Van Middlesworth and
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Murphy 1970, Grimm et al 1970) have convincingly demonstrated a slow 
turnover pool of iodine-125* The rats were fed a low iodine diet 
before the administration of iodine-125 and in this circumstance the 
biological half life of between 0,1 and 5*0 per cent of the dose 
exceeded that of the majority by up to 100 times. This persisting 
radionuclide could not be discharged with anti thyroid drugs and they 
now believe that the slow turnover is caused by incorporation of a 
variable proportion of iodine-125 into psammoma bodies*
To assess the importance of tliis in iodine-125 treated patients,
4 unselected fomalos who had received therapy doses, 10, 12, 36 and 43 
months previously wore investigated* Details of the ago of the 
patients and the doses prescribed are shown in Table B24* Each patient 
had a whole body count for iodine-125 over a period of 1,000 seconds. 
Room baokground counts wore ma,de over the samo length of time before 
and after each patient oowrb. To obtain a quantitative result a 
Imovm amount of iodine-125 was counted in a thyroid phantom passing 
under the body monitor: at the same speed as the patients. By 
proportion the reading which a standard of 1 uGi of iodine-125 would 
produce was calculated and from the formula
Patient count - average of room baoIcjea?Qund counts 
counts produced by 1 uGi standard
the amount of iodine-125 (uGi) persisting in each patient obtained.
One patient has 1.1 uCi remaining in tiie body 36 months after a
20.0 mOi dose, the remainder had less than this (Table B24)* The
greatest proportion of the dose persisting was 0.006 per cent 36 months 
after a second therapy dose of 7*5 mCi. TMs proportion is more them 
would be anticipated if the effective half life was 15 days. Althou^i 
the persistance of iodine-125 in the body has been demonstrated as long
as 43 months after treatment the amounts present do not contribute to a
significant environmental hazard.
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(3) Effeota of IûcLine-125 on Haemopoiotlc Tissues
(a) In the Production of Feraistent Oliromoaopal Aberrations in
Girculatinfc Lymt^ hocytea
Introduction
During metabolism of a therapeutic dose of radioactive iodine the 
marrow and the peripheral blood are irradiated at tliree phases (Green 
et al 1961), For a short time (few days) following absorption from 
the gastrointestinal tract the radioiodine is in the circulation as 
iodide until it is trapped by tlie thyroid and stored in the colloid of 
the gland. In this iodide phase both marrow and peripheral blood are 
subject to irradiation. Thereafter blood passing through the thyroid 
is also subject to radiation but most of the exposure at tliis later 
phase arises from circulating homone in the marrow and blood. This 
phase lasts up to 60 days if four effective half lives are considered 
to represent 94 por cent of the total irradiation exposure.
After 10 lifli of iodine-131 for thyr'otoxicosis the blood receives 
approximately I7 to 23 rads (Green et al 196I) and the possible effect 
of this irradiation has been studied by examination for chromosome 
damage after culture of the circulating lymphocytes. Chromosomal 
aberrations have been detected regularly after standard therapeutic 
doses of iodine-131 for thyrotoxicosis and also after much larger doses 
given in the treatment of 'kliyroid oanoer (Boyd et al 196I, MacIntyre and 
Dobyns 1962, Hofal and Beierwaltes I964, and Oantolino et al I966).
There are certain potential hazards with iodine-125 therapy, in view of 
the long half life (60 days) and the unusual radiations emitted from 
this radionuclide; about 60 per cent of the dose from a point source 
of iodine-125 is electronic with paths less than a few microns, the 
remaining being "soft" x-rays or gamma rays (Gillespie et al 1970)*
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Chromosomal analysis of circulating lymphocytes from patients treated 
with iodine-125 have been undertolcen to study tlje effects and to 
compare with previously documented iodine-131 induced aberrations#
Patients Studied and Procedures
Five female patients (average age 59*6 years, range 51*69 years) 
who had previously received iodine-125 therapy were talcen at random;
10 mis, of venous blood was removed for the lymphocyte culture and 
chromosome examination* In Table 3325 the age of each patient, the 
dose of iodine-125 and the latent period till the time of the study 
are listed* Venous blood from four females who had not received 
iodine-125 therapy was used for control information* Hone of the 
patients had been exposed to tid.ditional liigîa levels of radiation 
although each îiad received diagnostic tracer doses of iodine-131 (5 uGi),
Culture of blood and ciiromosomal analysis was carried out by 
Dr* M*A. Ferguson-Smith* Whole blood cultures were made using 0*5 ml* 
of heparinised venous blood and 4*5 ml* of liam's F.IO medium containing 
10 per con'b calf seruun* The cultures v/ere incubated for 72 hours in 
the presence of phytohaemagglutinin and treated in the last 2j hours 
with deaootylmethylcolchicine before being harvested by the routine 
air-dried technique* 100 cells were analysed by direct microscopy in 
every case except one (where only 50 cells were avfiilable for analysis), 
Ohromoeoine and chroma.tid aberrations were scored, but the control and 
Irradiated subjects were not identified by the oytogenetist until after 
the analysis was complete.
Results
Table B25 also gives details of the number and type of chromosome 
and chromatid abnormalities detected in cultured lymphocytes from each
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of the five patients who had received iodine-125 as well as the control 
patients. The aberrations were most nmerous in the patients treated 
with iodine-125 only 10 weeks before the study and least oomiuon in one 
patient who had tîxerapy 11 months before. All of the iodine-125 
treated %)atients had dicentric and ring fomatlons which are extremely 
rare in normal people. These abnormalities are generally characteristic 
of radiation eixqiosure £md have been described after iodine-131 therapy 
too. It is of importance that no cliromosome abnormalities were found 
in the lymphocytes of the unirradiated control subjects, the chromatid 
changes in tliis group were considered to be normal findings*
Discussion
Tills study shows unequivocally that iodine-125 in therapeutic 
doses causes a significant number of chromosome aberrations in the 
circulating peripheral lymphocytes of the type usually associated with 
radiation injuries? the evidence of damage persists for as long as 11 
months after therapy. The alterations produced in the peripheral 
lymphocyte chromosomes are similar to tliose found after iodine-131 
treatment (Boyd et al 1961, Maointyze and Dobyns 1962). They are 
also similar to those demonstrated after iodine-131 irradiation of the 
ra,t thyroid follicular cells* In this case the ohroraosome abnor­
malities being demonstrated after culture of the irradiated thyroid - 
follicular cells (Speight et al 1968).
The majority of the electronic emissions from iodine-125 an 
described in Section A, Chapter II, are low energy electrons, over 95 
per cent of wMoh travel in fluid or tissue less than 1 micron. It 
seems unlikely, therefore, that these low energy electrons oould cause 
lymphocyte damage in the marrow or in tlie circulating blood, Iodine- 
125, however, also emits x-rays otid gamma rays (about 40 per cent of 
the dose) from a point source end both of these, particularly the
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latter which has a tissue half life distance of up to 7 oms*, might 
irradiate marrow and tii© blood cells uniformly. Gillespie et al 
(1970) lu»;ve calculated that 10 iiiîi of iodine-125 mi^t subject the 
blood to 4 rods and about 1 rad of this would be due to the x-rays or 
gamma rays. Even if all the emissions are considered iodine-125 
gives less radiation to the blood tlian a therapeutioolXy equivalent 
dose of iodine-131*
'Bie main concern about blood and marrovf radiation is that the 
cytogenetic aberrations mi^it be associated with the later development 
of loulcaemia. There is a large body of Information intimately linking 
genetic alterations with the induction of eanoer. Certainly external 
% irradiation both therapeutic (Court Brown and Doll 1957) &&d 
accidental (Honmn et al I964) cause an increase in leidcaemia rates 
and in adults the data is suggestive of a dose-effect relationsliip. 
Although there are single case reports of leukaemio, occurring in patients 
previously treated vdth iodine-131 neither Pochin (1960) nor Saenger et 
al (1968) found on increase in the incidence of leulcaeraia after 
Burveyanoe of about 40,000 patients over 10 years or so* Certainly 
massive doses of iodine-131 (up to 200 raOi) given for the treatment of 
thya?oid oanoer ore associated with a definite rise in the incidence of 
leukaemia (Pooliin I960). It appeal's, therefore, that the ohromoscsn© 
abnormalities noted in the peripheral lymphocytes of iodine-131 treated 
thyroto^ cio patients are not associated with loulioemia, but is tliis also 
to be true following iodine-125 therapy? Colls exposed to radiation 
sufficient to cause gross visible abnormalities are likely to be 
sterile and althougta they may live and function for a long time as 
most circulating lymphocyWs appear to do, if tMs is the case the 
lymphocyte abnormalities of the type found after iodine-125 treatment 
may likewise carry no serious risk. More subtle but undetected 
alterations such as minor biochemical changes in D.H.A* perhaps even
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involving single genes, might however he present too. For this reason 
the risk of leukaemia after iodine-125 cannot he dismissed until the 
length of follow up has been considerably increased.
(b) As a Possible AetiologioaX Factor in the Production of 
Thrombocytopenia.
One significant haematologioal problem did develop shortly after 
iodine-125 therapy. A 48 year old female was treated v/ith 14*0 mCi 
(350 uOi per gram thyroid) on 24*9*71 and because of the severity of 
her disease propranolol 10 mg. four times per day was introduced at the 
same time. On 10.11.71 at a routine clinic visit slie was noted to 
have several bruises which could not be attributed to trauma and Hess 
test was positive. Platelet count was 34,000 per im and üie patient 
was admitted to hospital for more detailed investigations.
Although the thrombocytopenia worsened haemoglobin and red cell 
absolute indices, white cell count and blood film were repeatedly 
normal. Sternal marrow aspirate was hypercellular and the mega­
karyocytes were normal both numerically and morphologically. The one 
positive diagnostic test homogeneous antinuclear factor at a dilution 
of 1 in 64 allowed the diagnosis of thrombocytopenia secondary to 
systemic lupus erythematosus to be made. Dramatic improvement of the 
thrombocytopenia followed the introduction of prednisolone 60 mg. per 
day and it has now been possible to discontinue the steroids completely 
with no evidence of haematologioal relapse to date.
There are three possible explanations for the occurrence of 
thrombocytopenia in this patient. The diagnosis which has been 
accepted is systemic lupus erythematosus and in retrospect the patient 
did have a histo37y of joint pains and had mild arthritic changes In 
her hands consistent with this. Tlie radiation dose to the marrow 
from 14*0 mOl iodine-125 would liave been about 6 rads. Following
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radiation platelets are less severely affected than granulocytes. With 
doses of radiation which cause 90 per cent mortality thrombocytopenia 
may he total hut in tliis patient the level of radiation would not he 
expected to cause a severe fall in platelets (Oronkite et al 19&9).
None of tlie patients who received larger therapy doses in some instances 
three times as much had any bleeding problem 'though routine platelet 
counts were not done. Tiirombooytopenia secondary to marrow radiation 
dam&ige has been noted in Marshalleso islanders but no haoraorrhagic 
lihenomena were encountered (Oonard et al 19^9)* It is usually found 
in association with a diminished number of megakaryocytes or a totally 
hypooollular marrov/, therefore, the histological findings in this 
patient do not substantiate the conclusion that iodine-125 caused the 
'bhrombocytopenia. The final possibility is that propranolol produced 
this haematologioal abnormality, so far tliis relationship has never been 
described, but as a precaution the drug was discontinued.
(4) Extrathvroidal Radiation Effects of Iodlne-125
(a) On Parathyroid Function
Introduction
The energies of the radiations of iodine-125 are completely 
deposited within the thyroid, however the photon radiations which 
account for about 20 to 25 per cent of the total dose travel several 
centimetres in tissues (Table A9)* The dose to extra'fchyroidal tissues 
is mostly due to the X and X rays with energies greater than 4 Kev.
For those emissions the effective mass absorption coefficient in soft
2tissues is 0.19 cm per gram and from tliis value 1 mOi iodine-125 in 
a gland weighing 25 gram and a "thyroidal uptalce of 70 per cent the dose 
rate to adjacent tissues is 0.20 rad per horn? (Greig 1970). The dose 
rate at 1 cm from the thyroid assuming the same gland mass and dose 
uptake is 0.05 rad per hour per mOi iodine-125* If the effective half
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life of the radionuclide in the thyroid is 15 days the total doses per 
administered mOi iodine-125 are about 100 rads at the gland perimeter 
(paratliyroid) and about 25 rads at a distance of one centimetre (larynx). 
Extrathyroidal tissues including the parathyroids are therefore 
irradiated and it is important to know whether iodine-125 therapy 
reduces the function of these glands. No patient treated with iodine- 
125 had Glird.cal evidence of hypooeloaemia.
Calcium Homeostasis in Thvrotoxioosis Before and After Treatment
In tliyrotoxicosis parathyroid function is suppressed. Evidence 
of this includes reduction in the excretion of urinary phosphorus 
(Harden et al 1963) and diminished phosphate clearance (farsone and 
Anderson 1964)* Suppression of parathyroid secretion probably results 
from excessive release of bone mineral which is laiown to occur in 
thyrotoxicosis. The reduced parathormone level helps maintain the 
serum calcium witliin the normal range in most patients though if 
calcium mobilisation is gross even this compensation may not prevent 
hyperoaloaemia. In the face of persistent demineralisation of bone, 
heavy urinary and faecal losses of calcium occur resulting in a 
negative calcium ba3.ano© (Baxter and Bondy 1966).
That calcium homeostatis may bo altered after surgical treatment 
of thyrotoxicosis is vddely accepted. Acute hypooaloaemia severe 
enou^ to cause tetany may occur and up to 28 per cent of the patients 
can be shown to have a reduced parathyroid reserve (Jones and Fouman 
1963). Tlie vehement protests of the surgeons that parathyroid damage 
during operation is not the cause of hypooaloaemia has recently gained 
acceptance and Michie et al (l97l) believe that the rapid correction 
of the negative calcium balance may be a factor especially in the acute 
situation.
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There ore few critically analysed reports of hypooaloaemia 
occurring in thyrotoxic patients treated with iodine-131 (Table A2).
The doses prescribed v/ere not excessive and the absence of this 
problem in patients subjected to large doses of iodine-131 for the . 
treatment of thyroid cancer suggests that radiation damage has not 
been the sole cause of hypooaloaemia. Despite this if iodine-131 
treated patients with normal resting serum calcium levels are 
subjected to artificial reduction of the calcium between 10 per cent 
(Adams and Ghahners 1965) and 23*5 per cent (Better et al 19&9) havo 
a diminished parathyroid reserve.
Patients Studieds Methods
An infusion of disodium hydrogen EDTA (70 mg. per Kg. in 200 ml.
5 per cent dextrose) was given to 8 patients who had previously 
received iodine-125 (details of the patients studied are summaazlGed in 
Table B26). One patient was tested twice, once while thyrotoxic and 
then after she had developed hypothyroidism and was on replacement 
thyroxine. The infusion was given over 30 minutes and venous blood 
without constriction removed before and immediately after the infusion 
and at 2, 6, 12 and 24 hours post infusion.
Serum calcium was measured by E.B.T.A. titration in 8 of the 9 
patients and by flame photometry in 8 of the 9 patients* Serum 
phosphate levels and serum magnesium wore also measured in the 9 patients.
Results
Table B2? shows the results* The preinfusion calcium levels 
measured by flame photometry ranged from 8.5 to 10.4 mg per 100 ml.
(mean 9*3 mg per 100 ml). 24 hours after E.B.T.A* infusion the range 
of results was 8.4 to 10,0 mg per 100 ml (mean 8.9 mg per 100 ml)
(3? as 0.5)* No patient failed to restore the calcium level back to 
witliin 90 per cent of the basal level in 24 hours. Three patients
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(one on two occasions) failed to reach 90 per cent of the pre-infusion 
result in 24 hours when the estimations were made by B.D.T.A, titration* 
The serum phosphate fluctuated considerably and 24 hours after infusion 
ranged from 72 per cent to I69 per cent of the basal results* Serum 
magnesiujii levels were very stable, the 24 hour* post infusion value
ranging from 94 per cent to 106 per cent of the basal readings (average 
pre and post infusion results 1.92 and 1,89 mg per 100 ml respectively).
Discussion
B.D.T.A. is a chelating agent which binds calcium? intravenous 
infusion of B.D.T.A. rapidly lowers the level of calcium in the plasma. 
In physiological circumstances the stimulus of hypooaloaemia increases 
parathormone secretion and witliin 24 hours the calcium level is restored 
to at least 90 per cent of the basal level (Jones and Fourraan 1963).
The dose of E.D.T.A. employed, JO mg per Kg body wei^t, produced a 
satisfactory hypocalcaemio response many of the patients developed 
paraesthesiae in their hands and lips but in no instance did the test 
have to be reversed. Calcium for intravenous administration was 
always close to hand.
Using this stress none of the patients had deficient parathyroid 
reserve as defined above when the measurements were made using flame 
photometry. By B.D.T.A. titration 3 of the patients failed to raise 
the calcium to 90 per cent of the basal reading. Patient Number 2 
was miru.mally thyrotoxic and her post Infusion result of 8.7 mg per 100 
ml was normal in this oiroumstance. She was reinvestigated (Number 8) 
at a time when she was hypothyroid but on thyroxine therapy end the 
response was less adequate suggesting that she probably had impaired 
parathyroid reserve. The other patient (Number 3) who just failed to 
reach the normal, range (89 per cent) had a very severe hypooaloaemia
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4*7 mg per 100 ml immediately after the B.D.T.A. infusion and the 
reoovery was therefore fairly satisfactory. In the remainder of the 
patients the calcium results were normal.
Parathyroid reserve as stressed hy B.B.T.A. infusion is, therefore, 
not impaired in patients previously treated with iodine-125# Serum 
parathormone levels were not mea,sured. It has been suggested that 
parathyroid damage might be masked by a concomitant reduction in 
calcitonin because of irradiation of thyroid 0 cells. Tliis suggestion 
is not tenable for two reasons. Calcitonin is now laiom to be 
produced in extrathyroidal sources and secondly the rise in calcium 
after E.D.T.A. poin/bs to some agent actually mobilising bone mineral, 
i.e. para;bhormone.
Bimilar studies in iodine-131 treated thyrotoxic patients using 
B.D.T.A. (Adams and Chalmers 1965) or molar phosphate (Better et al 
1969) have demonstrated impaired parathyroid reserve. CChe Y  radiation 
from a standard dose of iodine-131 produces about 4OO to 5OO rad which 
is probably less than the Y  emissions from 10 to 15 mCi of iodine-125o 
It is possible, therefore, that the electronic radiations from iodine- 
131 which travel up to 2,000 microns may add to the Y radiation dajnage 
to the parathyx'oids, whereas the ,8 rays from iodine-125 would not 
produce this summation effect.
The mærked fluctuations in phosphate levels are difficult to explain 
but they do not correlate with the post infusion calcium levels.
Patients 1, 4, 5 and 6 had 24 hour post infusion phosphate levels which 
were between 115 per cent and I69 per cent of the basal readings yet in 
each of them the calciim response was normal.
It is thought that in thyrotoxicosis the proportion of magnesium 
bound to protein is increased compared to euthyroid or hypothyroid 
patients. Overall the total level is not affected and the basal levels 
wore normal in the patients studied. Ho statistical change in serum
magnesium levels was found after B.D.T.A. infusion.
(b) On Larynx
External radiation has been cited as an aetiologioal agent In 
laryngeal neoplasia, (Goolden 1957)* A 57 year old female complained 
of hoarseness 20 months after a 20 mOi therapy dose of iodine-125*
Investigaklon showed a polyp on her left vocal cord which has now been 
surgioei3.1y treated. histologically the polyp showed no evidence of 
malignancy. Alttaough it would bo throng to exclude the iodine-125 
therapy as being the cause of this lesion the most probable factor has 
been excessive cigarette smoMng.
(5) Effect of Iodine-125 on the Oourse of Exophthalmos
Routine ophthalmomotrio measurements were not recorded in the 
majority of patients, the impression obtained, however, vfas that iodine- 
125 did not adversely affect the eyes. 'J?wo of the 265 patients did 
require definitive treatment for ophthalmic complications which progressed 
after 'the radioiodine therapy. A 46 year old male was treated with high 
doses of prednisolone for severe proptosis, the outcome was excellent.
This patient is eu-thyroid 20 months after trea'fcment. A lateral 
tarsorrhaphy was necessary in a 66 year old femal.e who had become hypo­
thyroid 3 months after a dose of 15.O mCi. This incidence of ophthalmic 
complications is, therefore, well within the expected range (Wemor 1971)*
(6) Incidental Complications and Hazards
The spectrum of Illness encountered did not appear increased in a
group of 265 patients. Two females both aged 74 years at the time of 
therapy have died. On© had a cerebro-vascular accident 2 montlis after 
the dose while she was still thyrotoxic, the other died because of an
acute myocardial infarction. Doth patients died in other hospitals
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and no post mortem was carried out, the thyroid glands in particular 
were not examined.
A 58 year old patient suddenly became paraplegic 10 months after 
a 8,0 mCi drink. Investigation has proven that the underlying disease 
process was a bronchogenic carcinoma witli vertebral métastasés. 
P^uberculous endometritis, severe pulmonary embolus and a mild hemi- 
paresis have occurred in each of three patients and a fourth patient 
attempted to commit suicide.
Van Middlesworth (1972) has also dravai attention to a potential 
hazard of iodine-125, namely prolonged environmental radioactive 
contamination from saliva of patients treated v/iidi this radionuclide.
Ho has shomi that one week after a 10 mCi therapy dose of iodine-131 
that the patient mi^t transfer 0.001 to O.O8 mOi of iodine-131 to a 
postage stamp. Because of the longer half life of iodine-125 he has 
suggested that contamination mi^it persist for as long as one year.
On careful scrutiny of his data the radiation levels have been quoted 
in millicuries rather than raicrocurios and hence are exagerrated by a 
factor of 1,000. Althou^i the correct lower levels (O.OOl to O.O8 
uCi) cannot be completely disregarded they do not contribute to a 
significant environmental hazard.
Stmansonr
Therapeutic doses of iodine-125 have not so for been associated with 
any major complications. Persistant chromosomal aberrations are found 
in circulating lymphocytes, but it is hoped that they will like those 
encountered in iodine-131 treated patients not be associated with any 
malignant alteration. Parathyroid function appears intact and 
environmental contamination not excessive.
Section 0
Measurement of the RadiohiologicaX Changes 
in the Thyrotoxic Thyroid due to Iodine-125
Functional Statue of the Thyroid Following Iodine-125 Therapy
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întroduotion
Three different in vivo techniques and in vitro investigation of 
serum from iodine-125 treated patients have been used in an attempt 
to measure radiohiologiOal changes in the thyrotoxio thyroid after 
therapy. Firstly routine radioiodine-131 tests (24 hour thyroidal 
uptake of a tracer dose of iodine-131. the 48 hour protein hound 
iodine-131 and butanol extractable iodine-131) are described.,
Secondly using a modified intravenous perchlorate discharge test 
patients were studied to assess whether a defect in organic binding 
of iodine could be demonstrated. To complement this in vivo test , 
sera from iodine-125 treated patients were examined electrophonetioally 
and radiochromatographically for the presence of circulating iodoproteins 
labelled with iodine-125. Finally a study of serum thyroxine, T3 resin 
and serum thyrotropin (T.S.H.) levels related to the clinical assessment 
of each patient’s thyroid status is described and the importance of 
elevated serum T.S.H, in this context discussed.
( a) Routine Iodine-131 Teats in Patients Treated v/ith ÎQdlno-125
Patients Studied
The fmiotional ability of the thyroids of patients treated witli 
iodine-125 was investigated using routine iodine-131 tests* HSiirty 
miseleoted patients, 26 females and 4 males, eaoh received a 5 uOi 
tracer dose of iodine-131 at an average time of 14 months after tlie 
therapy dose* The 24 hour thyroidal accumulation of iodine-131 was 
measured by directional counting and calculated as a percentage of the 
total dose# A venous seu'flple of blood was withdravm 48 hours after the 
admni strati on of the tracer dose for measurement of the total plasma 
iodine-131 and the protoin bound iodine-131# Butanol extractable 
iodine-131 was measured in 21 of the 30 blood samples*
The 24 hour uptake of iodine-131 before therapy had been estimated 
in all of these patients but the tota,! protein bound radioactivity and 
protein bound iodine-131 levels were only available in 19 patients*
The reason for tliis was that the other 11 patients had been refeinzed to 
the Department of Nuclear Medicine with the diagnosis of thyrotoxicosis 
substantia'bed by biochemical investigations and the only confirraatorj»' 
tost carried out was the 24 hour uptake of iodine-131. Those paxî- 
therapy investigations were compared with the post therapy results.
Results
The total results are presented in Table 01. Before iodine-125 
therapy the moan 24 hour tracer uptalce was 60*9 '* 11.8 per cent (mean 
- 18,D*). After therapy this had fallen to 37#8 - 11.6 per cent 
(Figure Cl) and this difference was statistically different (P O.Ol). 
The mean total plasma radioactivities before 0*78 per cent dose per 
litre and after therapy 0.84 por cent dose per litre were very similar
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as were total protein botind iodlne-131 levels, 0*75 cent dose 
per litre and 0.80 per cent dose per litre respectively, Of the 
thirty patients 5 were clinically thyrotoxic at the time of the post­
therapy tests; comparing their results with the remainder of the 
patiente (I'ahle Cl), both the 24 hour uptalœ {53*6 per cent) and 
protein hound iodine-131 (1,05 cent dose per litre) were greater 
than those in the euthyroid patients (34*4 per cent and 0.75 per cent 
dose per litre), The uptakes were significantly different (PO.Ol),
The mean percentage butanol extraotable iodine-131 wan 91.1 - 10.3 
per cent. In 3 of the 21 patients (14«3 per cent) less than 85 per 
cent (60, 68 and 81 per cent respectively) of the radioactivity was 
extracted.
Discussion
Following destructive therapy of tlie thyroid either by surgery or 
by radioiodlne-131, the interpretation of iodine-131 tracer studies may 
be difficult (Harden 1971)• Soley et al (1949) noted an elevated 
uptake in a euthyroid patient who had received iodine-131. In Silver's 
series (1968), 46 out of 51 patients who were clinically euthyroid after 
iodine-131 had an elevated 4^  hour protein bound iodine-131, 22 
euthyroid patients had both a raised 24 hour tracer uptaJce and a hi^
48 hour protein bound iodine-131. The reason for tlie elevated uptake 
after definitive therapy is that only a small thyroidal pool of iodine 
remains (Jefferies et al 195&# Berson and Yalov; 1954» Freedborge et al 
1952) and. the up tales of iodine-131 is exagerrated since tlie remaining 
segment of thyroid functions intensely to maintain normal serum 
thyroxine levels probably under tlie stimulus of raised circulating 
pituitary thyrotropin levels. There is evidence that the smallest 
intrathyroidal hormone pools are encountered in patients treated witli 
radioiodine-131 thougli a similar situation may be encountered in other
thyroid diseases such as Hashimoto's thyroiditis (Eokert et al I960, 
Buchanan et al 19&5), The hi^ values for the protein hound iodine- 
131 are also probably due to this same factor; the thyroid secreting 
hormone of specific activity. One other possibility for ttie 
high protein bound iodlne-131 is that a non active and non butanol 
extractable material is being produced by tlie thyroid tliou^ this is 
seldom found after iodine-131 therapy.
In the iodine-125 treated patients despite the significant fall 
in the 24 houx* tracer uptalce the 48 hour protein iodine-131 levels 
were elevated. Although the 24 hour uptalce of iodine-131 and the 
protein bound iodine-131 were higher in the 5 patients who were still 
olinically thyrotoxic in the remainder of the patients each unequivocally 
eutliyroid the protein bound-131 was in the "tliyrotoxio range" in 20 
(80 per cent). In fact, only 4 of the thirty post therapy patients 
had combined results in the conventional range for normality, Ttie 
uptake persisting after therapy is a more accurate guide to 
persisting toxicity after iodine-125 than elevated 48 hour protein bound 
iodine-131 levels, Tlie butanol extraotable iodine-131 was below 85 per 
cent in only 3 of the patients. It appears, therefore, that in the 
majority of the patients the hi^ protein bound iodine-131 results were 
not due to the formation of abnormal iodinated proteins, Iodine-125 
treated patients have a "small pool pattern" and in general produce 
active thyroid hormones. These results are in keeping with those in 
the next section (vide infra) wliich suggest that there is no block in 
iodination of thyroglobulin at the cell apex. They also confirm what 
is already Imoim in iodine-131 treated patients that radioiodine tests 
alone may be misleading and that they should not be accepted as evidence 
of persistant toxicity and the need to retreat tlie patient.
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(b) Intrathyroidal Organlo Binding of Iodine 
In Patients Treated with Iodine-125
Introduction
Iodide trapped by the follicular cell is rapidly bound to the 
tyrosyl radicals of mature colloidal thyroglobulin. The almost 
simultaneous occurrence of these steps mean that at any time in the 
normal gland there is either no free intrathyroidal iodine or only a 
minute amount. In certain circumstances the iodination step is 
inhibited leading to an accumulation of trapped iodine in the cell. 
Typically the thiouracil drugs interfere with organic binding (Silver 
1968, Klopowitz and Solomon 1971) as do pharmacological doses of 
inorganic iodine (V/olff 1969). Patients with acquired thyroiditis 
(Hashimoto's) exhibit this block in hormone synthesis (Morgans and 
Trotter 1957) and it is also encountered as a hereditary disease in 
some patients with goitre and hypothyroidism (Ingbar and V/oebar I968) 
often associated with nerve deafness (Pendred’s Syndrome),
Any build up of unbound intrathyroidal iodine can be demonstrated 
using perchlorate or thlooyanate. These drugs not only inhibit the 
mechanism responsible for the trapping of iodide but also discharge 
unbound iodine from the follicular cell. The "conventional" discharge 
test involves the administration of an oral tracer dose of iodine-131, 
the thyroidal content of the radionuclide is measured at intervals of 
30 minutes using a directional counter. 2 hours after the tracer dose 
500 mg. to 1,000 mg. potassium perchlorate is prescribed orally the 
directional counting is continued for a farther 2 hours and any fall 
in thyroid radioactivity is accepted as an indication of discharge of 
free intrathyroidal iodine. Unfortunately this protocol has poor 
reproducibility, is non quantitative and is relatively insensitive, 
and these problems are reflected by different procedures used by various
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Perohlorate Biaoharge »* Battent Data
Humber Sex Dose of Iodine*125 
(mOi)
Time of Test after 
Iodine~125 Therapy
1 F 12.0 5 months
2 F 17.5 22 months
3 F 20.0 25 months
4 F 10.5 1 week
5 F 7.5 12 months
6 M 8.75 3 months
7 F 8.0 2 months
8 F 5.0 12 months
9 F 20.0 19 months
10 M 20.0 18 months
11 F 13.5 7 months
12 F 12.5 7 months
13 M 20.0 2 weeks
14 M 7.5 6 months
15 M 15.0 25 months
16 M 8.75 3.5 months
17 F 7.0 10 months
18 F 15.0 2 months
19 F 7,0 3 months
20 F 15.0 5 months
21 F 12.0 2 months
22 F 15.0 6 months
Time from latest therapy dose in patients 
v/ho received more than 1 drink
groupe of investigators (Floyd et al i960, Basohieri et al 1963,
Stewart and Murray 1966) •
Iodine-125 irradiates the colloid-céll interface more intensely 
than the remainder of the cell. The apex of the follicular cell is 
recognised as the site of iodination of thyroglobulin (Stein and Gross 
1964) and, therefore, an aoourato tost of organic binding in patients 
treated with iodi,ne-125 io of paramount importance. Because of the 
disadvantages of the oral perchlorate discharge test a shorter but 
more sensitive and quantitative method (Gray et al 1972) has been 
employed to investigate the ability of the thyroids of 22 patients 
previously treated with iodine-125 to bind iodine.
Materials and Methods
Figure 02 outlines the basis of the test. Firstly, a standard dose 
of iodine-131 in a phantom was counted using a closely collimated 
directional counter 2” from the radiation source; the detector fed a 
continuous potentiometer recorder. The phantom was removed and the 
patient lay on a couch and the detector placed 2’^ above the neck over 
the region of the thyroid. 25 uCi iodine-131 (carrier free Sodium 
iodide-131, Radiochemical Centre, jbiiereham) was given intravenously 
through an Indwelling catheter and the neck radioactivity recorded 
continuously for 10 minutes* 200 mg of sterile sodium perchlorate 
(specially prepared by the Fharmaoy Department, Royal Infirmary, Glasgovf) 
injected throu^i the venous catheter and recording continued for a further 
10 minutes.
Fatients Studied
22 patients (16 females and 6 males) who had received iodine-125 
therapy at varying intervals from 1 week to 25 months were asked to 
return for this investigation* In Table 02 the number of patients.
9.e
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Percentà^ of Iodlne-131 Biæhar/?ed from TiTOOlds of Patients 
Treated witli iodinG-125 tTsing Intravenous Perchlorate
Uptake of Iodine-131 Uptake of Iodine-131
Percentage of Standard Percentage of Standard Percentage of Total D
Humber Before Perchlorate After Perchlorate Discharged from
1 27.6 24.7 0.19
2 22.0 21.1 0.12
3 77.8 77.8 0
4 75.0 76.2 0
5 14.1 14.1 0
6 121.1 121.1 0
7 127.6 135.7 0
8 54.9 53.3 0.28
9 46.0 44.2 0.26
10 51.6 53.5 0
11 84.5 85.2 0
12 86.7 88.1 0
13 131.4 121.4 1.44
14 121.3 124.7 0
15 30.8 30.0 0.11
16 31.4 29.4 0.26
17 79.8 64.4 2.04
18 Tost not completed
19 27.2 25.6 0
20 45.7 42.5 0.43
21 42.7 42.7 0
22 28.4 28.7 0
mean 63.2 62.1
S.D. 37.6 38.2
their sex, the dose of iodine-125 administered (mOi) and the time 
between the therapy dose and the perchlorate discharge test are shown.
Results
One of the patients (Number 18) could not tolerate the directional 
counter over her neck and in her case the test was discontinued. !Ehe 
results are shown In Table 03. The level of radioactivity 10 minutes 
after the intravenous iodine-131 has been expressed as a percentage of 
the radioactivity of the known standard and the percentage of radio­
activity 10 minutes after the intravenous administration of sodium 
perchlorate listed in the adjacent column. The mean results before 
(63.2 - 37.6 per cent) and after perchlorate (62.1 - 38.2 per cent) 
are not statistically different.
A better and more meaningful method of expressing the results is 
from the formula
Y
X % 100a.—II !■ iiiaw n i i n in.« jkiW m.
25.0
where 3-34 = standard dose of iodine-131 (uGi)
X « number of units for count of standard dose (Figure 02)
Y K* number of units of discharge (Figure 02)
25.0 « amount of intravenous iodine-131
This expression ca3,culates the actual percentage of the dose of 
iodine-131 which is discharged from the thyroid in the 10 minutes after 
the intravenous administration of 200 mg. sodium perchlora,te. The 
results are shown in oolumn 4. Only 2 patients, numbers 13 and 17, 
have a positive discharge (greater than O.5 per cent of administered 
dose) hence an inhibition of iodination of 'liiyroglobulin.
Discussion
Tlie 20 minute intravenous perchlorate discharge test has been shown
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to be exqïdeltely sensitive in detecting subtle degree of impairment 
of iodine binding (Gray 1972). In a large number of patients with 
no thyroid disorder and in patients with untreated thyrotoxicosis the
fall in thyroidal radioactivity never exceeds 0.5 per cent of the 
administered dose (Gray et al 1972). Therefore only 2 of the 21 
patients (9*5 per cent) exiiibited a positive discharge (Figure 03).
Defects in intrathyroid organic binding of iodine have been 
detected in iodine-131 treated patients by Kirkland (1954) using oral 
sodium tîiiocyanate and by îfieffer et al (19&5) with oral perchlorate. 
Patients treated witîi standard or low doses of iodine-131 ar*e undulÿy 
sensitive to small doses of inorganic iodine (Hagen et al 19&7# 
Bravorman et al 19&9) and often develop hypothyroidism soon after 
iodine administration. This usually indicates defective organic 
binding and undoubtedly tlie rapid onset of hypothyroidism is exagerrated 
by the diminished intrathyroidal stores of preformed hormones in thyro­
toxicosis.
The remorkablo feature of tills study is that only two of tlae 
patients showed a defect in organic binding, yet because of the physical 
properties of iodine^l25 described previously (Section A, Chapter II) 
this radionuclide ratiier than iodine-131 should decrease iodine 
Incorporation into thyroglobulin. The test itself has been shown to 
be successful in the diagnosis of minor degrees of deficient binding 
and indeed has been better than the oral test in this respect. The 
teclinique does not appear to be at fault. It is possible that the 
inliomogeneous Irradiation of follicular cells by iodine-125 does not 
pertain to the "human model" altliou^ evidence that it does will be 
presented in Section C, Chapter II. The obvious explanation is that 
iodine-125 simply does not produce a defect in iodination in the 
majority of patients and the reduction in thyroidal activity is not 
due to impairment of this mechanism.
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(c) "In Vivo" Labelled Radioactive lodoproteins in 
the Circulation of Patients Treated with Iodine-125
(i) Thyroid Binding Proteins 
Introduction
In physiological sates mature thyroid hormones (thyroxine and 
triiodothyronine) are transported in the circulation in loose combination 
with an interalpha globulin (T.B.G,), prealbumin (TBPA) and to a lesser 
extent albumin (T.B.8.A.) (Oppenheimer I968, Oppenheimer and Surks 1971)» 
Thyrotoxicosis does not qualitatively alter this general pattern (inada 
and Sterling 19 7^) • The binding proteins with the exception of albumin 
are present in such small amounts that they are not detected on stained 
electrophoretic stripsj they can, however, be suitable "labelled” with 
radio!odinated thyroid hormones and detected by radioohromatographio 
scanning of the electrophoretic strips. A simple "in vivo" method of 
labelling these proteins or any abnormal protein carrying radioiodine 
is to give the patient a tracer or therapeutic dose of radioiodine and 
scan electrophoretic preparations for radioactivity.
There are reports of macroglobulins, probably thyroglobulin occurring 
in the circulation of patients treated with iodine-131 (Robbins et al 
1952, Tata et al 1956) and also in rats given large doses of iodine-131 
(Jovanovio et all969). Sera from patients treated with iodine-125 
were studied for evidence of alterations in the binding of iodine-125 
containing thyroid hormones and for the possible occurrence of abnormal 
circulating proteins such as thyroglobulin^
Patients Studied and Methods
The sera of 5 patients treated with iodine-125 and 2 patients treated 
with iodine-131 were studied. The age and sex of the patients, the dose 
of iodine-125 prescribed and the delay between therapy and the
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investigation are shown in Table C4. Also shown are the approximate 
apical and nuclear rad doses and the eventual therapeutic outcome.
Sera from 3 of the iodine-125 group were studied by standard paper 
electrophoresis, one by cellulose acetate electrophoresis and one by 
both techniques* Only paper electrophoresis was used for investigation 
of the iodine-131 treated patients. Tlae radioactivity of tlie "in vivo" 
labelled thyroid hormones was measured by radioohromatographio scanning 
(Packard).
Results
Ho difference was found in the radiosoans between patients who 
received iodine-125 or iodine-131. Figure 04 diagrammatically shows 
the radiochromatogram scan and paper electrophoretic strip of the serum 
from one of the iodine-125 treated patients v/Iiioh is representative for 
all the.specimens examined. The peaks of radioactive absorption 
corresponded with the interalphaglobulin and prealbumin bands and with 
one exception the pealc vfas higher in the former. Ho radioactivity was 
detected in abnormal thyroglobulins.
Discussion
Electrophoresis is the basic method of identifying the proteins 
which bind thyroid hormones and the radioiodine incorporated into the 
hormones after therapy is a convenient marker for these binding proteins, 
In each serum sample studied the radioactive pealc on both paper and 
starch gel electrophoretic strips corresponded with the normal thyroid 
binding globulin and prealbumin bands. Haere are reports of macro- 
globulins containing radioiodine being released into the circulation 
after widely differing doses of iodine-131 (Robbins et al 1952, Tata 
et al 1956). These macromolecules were almost certainly tliyroglobulin 
and the hypothesis is that the irradiation damage disrupts the follicle
1,00
to such an extent that 3.eakage of colloidal thyroglobulin occurs.
In the group of patients described this finding has not been 
oonfirTfled. Considering the whole group of patients it is possible 
that the investigations may have been carried out at the wrong time
abnormal
interval after tlaerapy for the detection of/thyroglobulin* For the
iodine-125 treated patients the delay of about 40 days corresponds to 
between 2 and 3 effective half-lives which should have been ideal for 
ma%3.mal damage. Tlie one patient studied 63 days after therapy may 
have been investigcuted too late. Jovanovio et al (1969) found that 
large doses of iodine-131 in rats caused release of a 198 thyroglobulin 
but that this had disappeared from the circulation 11 days after therapy,
Abnormal proteins are only detected by the method described if 
they are carrying radioiodine and it is possible that thyroglobulin 
%7as released but had no radioiodine incorporated or that the material 
had been deiodinated in the circulation.
It is attractive to suggest that the inhomogeneouB distribution 
of the follicle dose rate from iodine-125 anight have caused intense 
irradiation of the cell apex yet left the overall structure of the 
follicle intact. Two of the 5 patients eventually became hypothyroid 
pointing to a nuclear dose rate of considerable effect and the moon 
dose 10 microns from the apex was approximately 10,000 rads the dose 
rate towards the base of the cell may have been even loss allowing the 
basement membrane to remain intact. This mi,ght have been responsible 
for preventing release of these larger molecules.
(ii) lodothyronines. lodotyrcaines and Free Radioactive Iodine
Introduction
Apart from a minor binding defect in 2 patients, the intravenous 
perchlorate discharge test failed to demonstrate an intrathyroid block
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In the iodination ot thyroglohulin* To complement the in vivo 
investigations, sera from patients who had "been treated with iodine-125 
at Intervals from 10 days to 9 weeks previously were examined radio- 
chromatographically to study the pattern of radioactive iodinated 
moleoulea, iodothyronines and iodotyrosines in the oiroulation.
Patients Studied and Methods
Serum from 6 randomly selected patients who had received radio­
iodine-125 treatment from 10 days to 63 days previously was used for 
the investigation* Serum from 3 of the patients was studied in two 
occasions at different time intervals after treatment. In Table 04 
the age and sex of the patients, the dose of iodine*125 prescribed and 
the delay between therapy and the study are shown (4 of the patients 
were the same as in study i). For comparison, serum from two patients 
who had been treated with iodine-131 10 days beforehand was also studied, 
As a standard thyroxine labelled with iodine-131 was used.
5 mis. of test serum was extracted three times with butanol- 
thiosulphate and the pH of the extracts raised to 8 witli concentrated 
ammonia. The combined extracts were evaporated to dryness under 
reduced pressure and the residue resuspended in tliree parts methanol 
to 1 part concentrated ammonia and centrifuged at 3 >000 R.P.M. for 
5 minutes. Chromatograms were set up with the resulting supernatant 
solution on butanol acetic acid. Two specimens from iodine-125 treated 
patients were also subjected to panoreatin digestion and run on butanol 
ammonia. The chromatograms were scanned for iodine-125 or iodine-131 
depending on the therapeutic radionuclide the patient had received and 
scans compared with the iodine-131 thyroxine standard.
#02
tO R K IN SOLVENT FRONT
Radioohromatogram of serum from iodine«lS5 treated patients
A. Iodine-13X thyroxine standard* Sharp peak free
iodine*13X prolonged peak thyroxine*
B and 0* Serum from patients showing radioactivity 
corresponding with thyroxine standard,
Résulté
The chromatograms from each of the iodine-125 treated patients 
were hasioally the same and two représentative ones are shown 
diagramatioally (h) and (o) in Figure 05 under the thyroxine standard 
(a). In the standard the first sharp pealc is unbound iodine-131# the 
larger more protracted pealc is thyroxine. In each of the chromatograms 
from iodine-125 treated patients the sole radioactive peak corresponds 
to thyroxine (lodothyronine) and no free iodine-125 or iodotyrosines 
were isolated. The findings were the same after panoreatin digestion 
and butanol-ammonia chromatography.
Discussion
Circulating iodine is mostly found incorporated in mature thyroid 
hormones# thyroxine and triiodothyronine (iodothyronines) (Oppenheimer 
and Surks 1971)• There is some debate about the proportion of iodine 
in iodotyrosines in the circulation since some investigators believe that 
iodotyrosines are not found in the serum in physiological situations. 
Certainly these substances are found in the circulation of thyroiditis 
(Volp^ et al 1965)# they have been detected in almost 50 per cent of 
thyrotoxic patients (Farron et al 1959) and they occur in the 
oiroulation of rats subjected to prolonged feeding with iodine-125 
(Radichevioh and Wemer 1967)* The general belief is that they are 
normal constituents of the blood which are usually present in very 
small amounts (Rhodes I968).
Patients treated with iodine-125 mi^t be expected to have abnormal 
formation of thyroid hormones especially distortion of the process of 
iodination because of the intense apical radiation. Membrane 
destruction mi^t be associated with lealcage of free iodine-125 into 
the circulation. It is also possible that lodo tyro sine coupling
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be defective due to the extremely hi^ radiation dosee within the 
oolloid resulting in release of large quantities of iodotyrosines.
There is no evidence to support these hypotheses since the only 
circulating material containing radioactive iodine corresponded exactly 
with the thyroxine standard. The absence of free iodine-125 in the 
circulations of the iodine-125 treated patients is of interest especially 
since a very small amount of free iodine was detected in iodine-131 
patients.
The timing of the investigations was carefully selected. The mean 
effective half life of iodine-125 in the body is about 15 days and, 
therefore, post treatment sera at 10, 42 and 63 days gave a spectrum of 
times encompassing the probable maximum irradiation effect. In the 
iodine-131 treated patients the delay of 10 days was about twice the 
effective half-life which should correspond with the greatest damage.
The long half-life of iodine-125 and the recycling of iodine in 
the body are of theoretical importance. Patients treated with 
therapeutic amounts of iodine-125 can be thought of as "eicperimental 
animals" being fed iodine-125 over a prolonged period# Failure to 
demonstrate iodine-125 labelled iodotj'rosines (in these patients as 
long as 63 days after treatment) is therofore significant? labelled 
iodothyronines were detectable at all times throu^iout the study.
The normal results are in close agreement with the in vivo perchlorate 
discharge tests and suggest that if *Î3lie oxtranuclear effect of iodine- 
125 ie of tlierapeutio benefit it does not distort the synthesis of 
normal mature thyroid hormones. Because of the normal results the 
experiments were not expanded; it is very unlikely, however, that 
defective hormone production would be encountered at a later date.
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(d)
Levels in Patients Treated with Iodine-129
Reliable# sensitive and spooifio railoimmunoassays of serum T.S.H. 
have been developed (Odell et al I965» btiger 1965» Baud and Odell 1969, 
Hall et al 1971# Hall 1972 and El Kabir 1972) and are available for 
clinical use. The maini clinical importance of tliis estimation is 
diagnosis of hypothyroidism due to thyroid disease (Horshman and 
Pitiman 1971» 1971b, Htiger 1971# Mayberry et al 1971) where an elevated 
level is a sine qua non* In euthyroid subjects the values are low but 
because of the Insensitivity of current assays it has not been possible 
to separate euthyroid from thyrotoxic patients on the basis of serum 
T.B.H* levels alone, Theoretiosdly thyrotosdLoosis should completely 
suppress pituitary T.S.H. production, Normal levels of T’.S.H. are 
also found in hypothyroid patients who are regularly ingesting a 
sufficient dose of thyroxine (Cotton et al 1971)*
Ëadiolmmimoassay of T.S.ÏÏ, has exposed an interesting group of 
patients; they are classified as euthyroid on clinical grounds and have 
normal results for conventional biochemical tests of thyroid function 
yet they have elevated serum T.S.H* levels. They are best categorised 
as being subclinically hypothyroid (Editorial 1971a# Bvered and Hall 
1972), This condition may occur following surgical tliyroideotomy 
(Hedley et al 1971) and iodine-131 therapy (Slingerland et al 1970).
Tlie importance of serum T.S.H* levels in patients treated vdth iodine- 
125 is apparent. Professor Reginald Ha3*l of the Department of Medicine# 
Hniversity of Newcastle# very kindly agreed to undertake the radio­
immunoassay of T.S.H. The technique was s, double antibody assay as 
described by Hall et al (l97l) #
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Relation of serum thyroxine levels (mean * one standard deviation)
solid lines to serum thyrotropin levels (mean - one standard
deviation) interrupted lines in 6 groups of patients after iodine-
125 therapy
Group I Thyrotoxic
Group II Hypothyroid on replacement thyroxine
Group III Kuthyroid
Group IV Euthyroid with hi^ TSH
Group V ÎÆisolassified
Group VI Hypothyroid
Table 0 5
Tlxvrotropin Levela in îüu'toroidé Hvperthyroid 
and Hynotîr/roid Patients
(After Hall et al 1971)
number Mean Range Standard Deviation
normal Controls 29 1.6 Oo6 — 4.2 i 0.8
Hyperthyroid 18 1.0 0.5 - 1,7 i 0,4
Hypothyroid 19 17? 6.5 - 588 - 152
Patients Studied
20 mis. venous blood was removed from each of 99 unselected 
patients who were attending the Department of Nuclear Medicine for 
routine clinical assessment at varying time intervals after iodine- 
125 therapy. The clinical status of each patient was determined. 
Serum thyroxine (Thyopao 4* Amersham) and T3 Resin uptake (Thyopao 3, 
Amersham) levels were estimated for each patient* Depending on the 
combined clinical and laboratory observations each patient was 
allotted to one of 5 groups: thyrotoxic, hypothyroid but on
replacement thyroxine, euthyroid, wrongly classified as euthyroid and 
hypothyroid. A portion of each serum specimen was retained, given a 
coded number and frozen. 99 numbered serum samples without any 
clinical details apart from the therapy dose of iodine-125 and the 
date prescribed were dispatched to Newcastle where T.S.H. levels were 
measured. Tlie serum T.S.H* levels wore then studied in collaboration 
with the clinical and biochemical information.
Results
Table 05 is published by kind permission of Professor Hall and 
gives the expected T.S.H. levels in euthyroid, thyrotoxic and îiypo- 
thyroid subjects. The normal ranges for serum thyroxine and T3 resin 
are also shown. Details of the results in iodine-125 treated patients 
are listed in Table 06 and shown graphically in Figure 06.
Results
Oroun 1. Thyrotoxic Patients
24 of the 99 patients were clinically thyrotoxic and with one 
exception had raised levels of serum thyroxine 14*4 ug - 2.5 ug per 
100 mis (mean t one standard deviation). The mean T3 resin level 
(108.9) was above normal (79 * 105) but 7 of the 24 patients had
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results which were within the nomal range* Serum T.S.H. levels were 
low 1.6 - 1.4 ydi per ml hut one patient had an ahnonaally hi^ result 
(7.5 juTJ per ml).
Group II. Hypothyroid Patients Taking Thyroxine
7 patients who had been started on replacement thyroxine therapy 
had a mean serum thyroxine level of 12*3 ug per 100 ml. and their T3 
resin results were at the upper limits of nomality 102.4 * 9» 5*
The average T.S.H. level was well within nonml 2.2 pH per ml, one
patient, however, did have a high T.S.H. level (7.7 pH per ml.).
The euthyroid patients were divided into 2 categories depending 
on the serum T.S.H, levels; Group III normal serum T.S.H. î Group IV 
eleva,ted se:cum T.S.H. (an arbitrary level of above 5*0 uH per ml was 
accepted as an elevated result).
Group III.
39 patients all clinioally euthyroid had normal serum thyroxine 
(8.4 - 2.2 ug per 100 mis), T3 resin (93.2 - 9*8) and serum T.S.H.
(1.7 ^ 1*3 pH per ml).
Group IV.
17 patients originally classified with Group III since they 
appeared euthyroid had normal serum tliyro3clne (6.5 ^  2.1 ug per 100 
mis) and T3 resin (86.7 ^ 6.6). In each of these patients, however, 
the serum T.S.H. level was above 5.0 pH per ml (l3*9 " 14*9 uH per ml) 
One patient in particular had a very high level (66.0 uH per ml).
3 patients were clinically classified as being euthyroid but the 
serum th^ /roxine levels were reduced (4.0 - 0.6 ug per 100 mis), T3 
resin results in the low normal range (84.O - 8.2) and the T.S.H. 
levels elevated (26.6 - 21.2 per ml).
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Hypothyroid
9 patients had hioohemical evidence of hypothyroidism which was 
in keeping vdth the clinical assessment* In 'these patients the
levels were the highest of the 6 groups (34*5 ^ 18.1 utf per ml).
Discussion
In general tlie results obtained in Groups I# II, III and VI are 
as would he expected. The results in Groups TV and V provide 
interesting information that recfuires expansion. Before discussing 
these groups there were pax'adoxioal results in two patients which also 
need clarification. One thyrotoxic patient (Group l) had anomalous 
résulte of interest in that the serum T.S.H. level was elevated 
(7*5 UÜ per ml) yet she was clinically t'nyrotoxic and had an elevated 
serum thyi?oxlne (l6.0 ug per 100 ml). It is unlikely that an error 
was made in the radiolmmimoassay (Hall, personal comment). There 
may, however, have been a substance in the patient’s circulation which 
cross reacted with T.S.H* yet did not have thyroid stimuletting 
properties. It is equally possible that the cause of her thyrotoxicosis 
was, in fact, T.S.H. or T.S.H. like material. Rarely a oliromophobe 
adenoma may secrete T.S.H. (Hamilton et al 1970) but more commonly the 
material is produced by an ovarian or trophoblastic neoplasm (Odell et 
0,1 1963, Eershmam.: and Higgins 1970). There has been no clinical 
evidence of either of these possibilities and althou^^ repeat serum 
T.S.H. levels are not yet to hand tiie serum 'bhyroxine is persistently 
elevated.
The other patient (Group II) was on replacement Wiyrosdne. She 
had normal biochemical tests but a raised T.S.H. level, a combination 
encountered when therapy is not regularly ingested^
The patients in Group IV fall into the category of subclinioal 
hypothyroidism (Evened and Hall 1972). The importance of this
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condition is still open to discussion. Bastenie et al (1967, 1971) 
suggest that there may be an associated preponderance of athero­
sclerotic vascular disease but to date there have been no prospective 
controlled trials of treated and untreated patients to confirm or
refute this Iiypotliesis. In the context of iodine-125 therapy this 
group is extremely important* If the theory of reduced nuclear 
irradiation is correct it might be ex}5Gcted that the presently elevated 
serum T.S.H. levels will in the course of time fall and the overall 
tliyroid function remain virtually unaltered. This would be proof of 
cell regeneration and rc-establishmcnt of the normal physiological 
balance. However, if the cell nuclei have been permanently damaged 
or sterilised by the radiation a progressive rise in serum. T.S.H. with 
a reciprocal diminution in thyroid function must be anticipated and the 
outcome similar to that following iodine-131.
Iodine-125 mi^t have caused minimal, nuclear damage because of the 
low intensity radiation, yet may not have sterilised the cells. In 
this si'tuation a continued elevated T.S.H. stimulus might be dangerous 
since in the e^ qierimental animal this combina,tion can result in neo­
plastic changes. Boniaoh (l97l) believes that low doses of iodine-131 
may leave areas of the tloyroid capable of division and if toxicity 
persists or recurs there is a risk of induction of thyroid carcinoma.
Tlie same situation must apply in iodine-125 treated patients.
The 3 patients (Group V) who were wrongly classified are also of 
interest. On reappraisal without knowledge of the investigations they 
would still be classified as euthyroid, Hevertheless all the available 
bioolienoioal and radioimmunoassay evidence points to the fact that they 
are sub thyroid. Recent experimental evidence indicates that T.S.H. 
preferentially stimulates triiodothyronine secretion (Wahner and Gorman 
1971)* Triiodothyronine is not as potent as thyroxine in the inhibition
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of T.S.H. sGoretion (Editorial 1971b, c) and theoretically it is 
possible that tlie raised serum T.S.H. in these patients is causing 
an inappropriately excessive secretion of triiodothyronine. This
might be exagerrated by the preferential apical irradiation of the 
follicular cell although no block in iodination was demonstrated 
'supra). The patients, therefore., despite low serum thyroxine and 
high T.S.H. nii^t possibly have normal thyroid balance. Serum has 
been retained for triiodothyronine assay but as yet tlie technique is 
not reliable and confirmation of this hyjpothesis is not available. 
However, the close inverse relationship of serum thyroxine and serum 
T.S.H. levels ttirouglîout the series does suggest that no other factors 
are involved*
Mayberry et el (1971) have shown that the T.S.H. levels in hypo­
thyroid patients tend to be liigher in younger patients; in this 
series there is no such correlation*
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Section G
Chapter II
Is Iodlne-125 Different Prom Iodine-131?
Ill
Intï?oduotion
Comparison of the therapeutic outcomes in different groups of 
patients treated with radioiodine is difficult. There are variable 
factors which have to be considered when this form of treatment is 
prescribed. These Include the percentage of the therapy dose taken 
into the thyroid which may not closely mirror the uptalce of a 
diagnostic tracer dose and once in the gland the distribution of 
the radionuclide is often uneven subjecting some areas to a much 
higher radiation dose than anticipated and other regions to a lower 
dose. The sise of the gland, an Important measurement for dose 
prescription, is difficult to assess accurately even with the use of 
precise scans and mathematical formulae to transform the area of the 
gland to a volume. Radio sensitivity of follicular cells does vary
and is not simply a neat explanation for results which occurs 
unexpectedly. The outcome in apparently similar populations studied 
after similar radioiodine treatment schedules may, therefore, be quite 
divergent. Spencer (l97i) has by the use of simple mathematical 
techniques made comparisons feasible.
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400pCi PER GRAM [48 PATIENTS]
100
LU
05
NUMBER OF DOSES
Peroentage of imoua:ed patients (logarithmio scale) 
after one, two and three therapy doses of iodine-125 
who received from 351 to 450 nOi per gram of thyroid.
Table 0 (f
Response of Thvrotoxlo Tlxvrold to Iodine-131 
(Prom Bpenoer)
Humber of Hoses Humber of Hoses 
Rate Oonstmit for 3 0  cure per Patient
Silver (1968) 0.676 I.03 1.97
Maynard (1969) 0.936 0.74 I.6I
Hofal et al (1966) 1.121 0.62 1.43
Method
The pe'iîcentago of ■unc'urod thyrotoxic patients are related to the 
numher of therapy drlnlcs tha,t have been prescribed* A similar approach 
obtaining the same answer is illnstrated in Figure 0? where the 
percentage of unoured patients have been plotted by logarithmic scale 
on the Ordinate and the number of therapy doses prescribed poltted on 
the abscica* Using the results from the 400 uGi per gram of thyroid 
group (350**450 uOi) when zero therapy doses have been prescribed 100 
per cent of the patients are thyrotoxic after 1 therapy drink, 30 per 
cent remain thyrotoxic, 8 per cent are not cured by the second drink 
and 2. per cent are still thyrotoxic after a third therapy dose. These 
points are joined and the exact slope of this line is obtained by the 
method of least squares to give the rate constant (A ).
The fraction of patients remaining thyrotoxic continues to be
relatively constant from therapy dose to therapy dose. Because of
this the number of unoured patients can be expressed in terms of an
exponential equation
H pa HoO ^
Ydaere H « the number of patients still thyrotoxic
Ho the original number of thyrotoxic patients 
Ï) the number of therapy doses 
A  « rate constant
The rate constants in three iodine-131 treatment series (Silver 
1968, Maynard I969 and Hofal et al I966) have been calculated by 
Spencer (l97l) to be 0.676, 0.936 and 1.121 respectively (Table 07).
The increase in the size of the rate constant is indicative of a 
steeper slope to the response line and hence a more rapid rate of 
control of the thyrotoxicosis. The therapy doses of iodine-131 
prescribed by these investigators had been designed to Introduce 
respectively into the gland 80 uOi, 100 uOi and 185 uOi per gram of
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thyroid. The increase in the dose is> therefore, paralleled hy an 
increase in rate constant.
%he results obtained with iodlne*125 treatnient for thyrotoxicosis 
have been discussed in detail (Section B, Chegpter IX). Overall they 
appeared better than those achieved either Tdth standard or low doses 
of iodine»131. Bie total treatnient group, however, contains sub** 
groups of patients who received a variety of doses of iodine-125 and 
utilising the mathematical teciinique outlined above a rate constant 
has been obtained for the total g3?oUp of patients, for males and 
females separately and for patients who received 151*^ 250, 251-350# 
351-450, 451^550 and more than 550 uOi iodine-^ 125 per gram of tliyroid. 
%ie last of these combines the results of the three treatment groups 
who were given 551*^ 650., 651-750 and more than 750 uOi iodine-125 per 
gram of thyroid (groups 5, 6 and 7, Section B, Chapter II). Xhese 
were tahen together because of the small number of patients in each 
and because the outcome in the three groups wac almost identical.
9 patients have been excluded, they are made up by tliroo in whom the 
dose of iodine-125 por gram of thyroid was not Imown, three who 
received less than I50 uOi per gram and the throe patients who failed 
to return for review. tTsing tb.e rate constants a direct comparison 
Tfith the results in the iodine-131 treated patients of Silver I968, 
Maynard I969 and Bofal et al 1966 has been undertalcen.
Results
3he rate constant of the total group O.845 was simi.lar to that 
in females 0.845 and males 0.852 (Table C0). The result was low 
(0.503) in patients who received the smallest dose of iodine-125 
(151 to 250 uOi range) but as the dose increased the speed of control 
with one exception became more rapid and the rate constants greater 
(0.596, 1.272, 1.199 and 1.496)* The group who received a mean dose
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NUMBER OF DOSES 1251
Hate of control of tliÿrotoxicosis after iodine-125 therapy 
A* Patients treated with I5I to 250 uOi per gram of thyroid
B* Patients treated with 25I to 350 ^Oi per gram of thyroid
0, Patients treated with 351 to 450 uOi per gram of thyroid
of 500 iiGi per gram of thyroid was controlled slightly less rapidly 
than the group of 48 patients who 3?eoelved a mean dose of 4OO nOl 
iodlne-125 per gram thyroid#
Dlsouseion
0.845 the rate oonstsmt for the total treatment group of iodide- 
125 treated patients is similar to the rate constant for the Iodine- 
131 treated patients of Maynard (1969)» His therapy doses were 
calculated to administer 100 uGi iodine-131 per estimated gram of 
thyroid# nince, as has hoen explained, the total group contains a 
spectrum of dose schedules the discussion ^ vill he focussed on tîxe 
group teeated mth 351-450 uOi iodine-125 per gram of thyroid. l^ie 
rate constant in this group 1.272 was greater than that calculated for 
the iodine-131 treated patients of Hofal et al (1966)# An administered 
dose of 400 uOi iodine-125 per gram of thyroid is, therefore, superior 
to an intrathyroidal dose of IB5 uOi iodine-131 per gram of thyroid#
To obtai.ii such a rapid rate of control with iodine-131 a considerable 
number of "cured" patients rapidly became liypotliyroid and 2 years after 
therapy 4&*6 per cent of those patients were thus affected (Hofal et al 
1966). After a similar period of follow up in this iodine-125 treatment 
group only 10 per cent of the patients have become hypothyroid (Section B 
Chapter II). The excellent rate of control with an average dose of 4OC 
uGi iodine-125 pon gnam of thyroid han been obtained with a reduction in 
thyroid insufficiency#
A second method of defining the rate of response to radioiodine is 
the concept of the number of doses per patient required to cure 50 per 
cent of the total group# lliis figure is the result of the abscisca of 
the graph corresponding to 50 per cent on the ordinate (Mgnre 08)*
An alternative method of obtaini.ng the answer is from the formula
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X = XtQgio 100 I*ogl0 50
X  Lok 10 ^
V/here X = number of doees to cure 50 per cent 
A  a rate constant
In the patients treated by Silver (l$68) 1*03 doses were required 
for each patient to cure 50 per cent of the group (Table 07) but with 
the larger doses prescribed by Hofal et al (1966) this was reduced to
0.62 doses per patient. In the iodlne*125 treatment group who received 
351-450 uCi per gram of thyroid only 0*55 doses were required per 
patient (Table 08).
Puriher evidence of the diffeaænce between iodine-125 and iodine- 
131 is obtained by calculating the average number of doses prescribed 
for every patient in the treatment group* For example, if 100 patients 
received 1 drink, 100 patients 2 drinlcs and 100 required 3 drlnlcs the 
number of doses per patient
= (100 X 1) + (100 X 2) + (100 X « 2
300
Silver (1968) prescribed 1*97 doses per patient but with a progressive 
increase in the prescribed amount this was reduced to 1.61 drinks by 
Maynard (1969) end 1.43 doses by Hofal et al (1966). These results 
are also tabulated in 07 and the corresponding results in iodine-125 
treated patients in Table 08. I.36 doses were prescribed per patient
for the total group and in the best outcome group (351-450 uOi per 
gram) 1.35 doses per patient. Only 1.22 doses were required in 
patients given doses greater than 550 uOi per gram of thyroid.
The rapid rate of control in the 351-450 uOi group obtained with 
a low hypothyroid problem has required a small number of doses per 
patient and also a low number of doses for a 50 per cent cure. This 
superb combination of benefits cannot be obtained with iodine-131.
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Rate Constant (X)
Relation of rate constant (A) to the number of doses of iodlne-125 
to cure 50 P03? cent of patients in each treatment group
1. Patients treated with 151 to 250 uOi per gram of thyroid
2* Patients treated with 251 to 350 uOl per gram of #:^oid
3* Female patients treated with iodine-125 
4# Male patients treated with iodine-125
5. Patients treated with 451 to 550 uOi per gram of thyroid
6. Patients treated with 351 to 450 uCi per grsjn of thyroid
7* Patients treated with more than 550 uCi per gram of thyroid
A, . Results from Silver (1968)5 Iodine-131
B* Results from Maynard (I969): Iodine-131
G# Results from Rofal et al (1966)5 Iodine-131
One other fontor of note is that with large doses of iodine-125 (more 
than 550 uOi per g):am) the rate constant of 1*496 is outstanding*
Only 1*22 doses are required per patient and rapid one dose cure is 
much more common than with large doses of iodine-131* IChe "benefit 
of these large doses in the management of tliyroto:d.o patients vdth 
heart disease is obvious and although a definitive policy was reached 
not to undertaJce the treatment of eu’fchyroid oardiac patients suffering 
from intractable angina or cardian failm:e, iodine-125 in üiese large 
doses would appear to be more efficient than iodine-131 in reducing 
thyroid itmction.
The data from these oa3.oulations malce it possible to compare doses 
of iodine-125 and iodine-131 v/hioh have appro%lmate].y the same effect* 
The technique adopted has involved a combination of (a) the number of 
doses required to cure 50 per cent and (b) the rate constant* The 
rate constants of the iodine-125 treatment groups and the tliree iodine- 
131 reference series have been plotted against the number of doses in 
each of these which were required to cure 50 per cent of the group.
This is shown grapliically in Figmze 09# An excellent relationsMp 
is shown to exist and tlie omzve passes tlirough all of the points, 
iodine-131 treated as well as iodine-125 treated*
Overall tho outcome in all of the patients treated with iodine- 
125 is similar to that found in patients given an intrathyroidal dose 
of 100 uGi iodine-131 per gram. Administered doses of 400 uOi and 
500 uGi of iodine-125 per gram of thyroid give results similar to but 
slightly better than an intrathyroidal dose of 185 uOi iodine-131* 
Accepting that the average thyroidal uptWee of the therapeutic dose 
iodine-125 was 66 per cent of the prescribed dose approximately 264 
to 330 uGi per gram of iiiis radionuclide was introduced into the 
thyroid* The ratio of effectiveness of iodine-131 to iodine-125 
at these dose levels is, therefore, about l/l*5 - 2*0* At lower
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dos© ranges an admlnlatered dose of 300 uGi iodine-125 can be seen 
to be sll#itly less active than a thyroid dose of 80 uOi iodine-131*
The ratio of effectiveness in this case is 1/2*5.
Gnminarv
Using simple mathematical techniques iodine-125 has been shown 
to differ from iodine-131 in the following respects * Approximately
double the dose of iodine-125 is required to produce the same 
therapeutic effect as iodine-131 > but as the dose of radionuclide is 
decreased this ratio is increased to 2*5 to 1* Nevertheless for the 
same rate of control iodine-125 Causes considerably less hypothyroidism 
after a similar period of follow up. Large therapy doses of iodine- 
125 almost inevitably produce a rapid single dose cure*
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Final Oonoliiaions aaid Possible Extensions of învestlmtione
Iodine-125 iB succefôsfitl in the control of thyrotoxicosis and in 
the dose range of 351 to 450 u.Oi per gram of thyroid is superior to 
iodine-131o Obviously* no new therapeutic nuclide can he considered 
beneficial until it is shown to be as safe as the existing one.
Iodine-131 has stood the test of time and the original fears of 
increased inoidenoe of thyroid oaîïcer and leulcaémia following therapy 
have been partially discounted but this spectre still hangs over tlie 
use of iodine-125 ‘therapy (Editorial 1971» 1972 a# b) and extension 
of the length of follow up is important from tliis point of view.
With longer periods of surveillance any progressive rise in hypothyroidism 
will also be detected.
The exquisite simplicity of single dose radioiodine ‘therapy is 
important but more in-brioatc a])proaches using iodine-125 are probably 
justifiable in a limited number of patients. It is conceivable ‘that 
hypothyroidism could be completely eliminated wi’bh the prescription of 
very small dobes of iodine-125 (lOO uOi or less per gram of tliyroid).
What remains to be answered is whether this si%e of dose would 
even‘fcually control ‘bhe disease in all of the patients treated, almost 
certainly drug -fclierapy either conventional an'bithyroid drugs or beta 
adrenergic blockors or both would be required in a very large pro­
portion if no'b all of *Ü:ie patients.
An alternative approach v/ould be to prescribe a tailored dose to 
deposit, for example, 3,000 rads to the follicular cell nuclei. This 
would require accurate measurement of the effective half-life of 
iodine in each patient and also bxi accurate estimation of thyroid gland
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mass and if possible the peroentase of colloid in the l^and.
t!?here is another exciting: but as yet theoretical metliod of 
tailoring the dose for each patient. If an accurate index of 
decreasing thyroid function existed and it was possible to judge 
when "normal" 'üiyroid status reached after irradiation it would 
be theoretically possible to discharge the radionuclide from the 
thyroid using anti thyroid drugs*
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